<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26594176</article-id>
<article-id pub-id-type="pmc">4633518</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2015.00264</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Culhane</surname>
<given-names>Kelly J.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>†</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/249907/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Yuting</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>†</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/288561/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cai</surname>
<given-names>Yingying</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/287946/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yan</surname>
<given-names>Elsa C. Y.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/249978/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Molecular Biophysics and Biochemistry, Yale University</institution>
<country>New Haven, CT, USA</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Chemistry, Yale University</institution>
<country>New Haven, CT, USA</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Xavier Deupi, Paul Scherrer Institute, Switzerland</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Gian Marco Leggio, University of Catania, Italy; Andrea Bortolato, Heptares Therapeutics, UK</p>
</fn>
<corresp id="fn001">*Correspondence: Elsa C. Y. Yan <email xlink:type="simple">elsa.yan@yale.edu</email></corresp>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology</p>
</fn>
<fn fn-type="other" id="fn003">
<p>†These authors have contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>05</day>
<month>11</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="collection">
<year>2015</year>
</pub-date>
<volume>6</volume>
<elocation-id>264</elocation-id>
<history>
<date date-type="received">
<day>24</day>
<month>6</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>10</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2015 Culhane, Liu, Cai and Yan.</copyright-statement>
<copyright-year>2015</copyright-year>
<copyright-holder>Culhane, Liu, Cai and Yan</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Although family B G protein-coupled receptors (GPCRs) contain only 15 members, they play key roles in transmembrane signal transduction of hormones. Family B GPCRs are drug targets for developing therapeutics for diseases ranging from metabolic to neurological disorders. Despite their importance, the molecular mechanism of activation of family B GPCRs remains largely unexplored due to the challenges in expression and purification of functional receptors to the quantity for biophysical characterization. Currently, there is no crystal structure available of a full-length family B GPCR. However, structures of key domains, including the extracellular ligand binding regions and seven-helical transmembrane regions, have been solved by X-ray crystallography and NMR, providing insights into the mechanisms of ligand recognition and selectivity, and helical arrangements within the cell membrane. Moreover, biophysical and biochemical methods have been used to explore functions, key residues for signaling, and the kinetics and dynamics of signaling processes. This review summarizes the current knowledge of the signal transduction mechanism of family B GPCRs at the molecular level and comments on the challenges and outlook for mechanistic studies of family B GPCRs.</p>
</abstract>
<kwd-group>
<kwd>GPCR</kwd>
<kwd>family B GPCR</kwd>
<kwd>peptide hormone</kwd>
<kwd>G protein</kwd>
<kwd>activation mechanisms</kwd>
<kwd>signal transduction</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">National Science Foundation<named-content content-type="fundref-id">10.13039/100000001</named-content></funding-source>
<award-id rid="cn001">MCB-0955407</award-id>
</award-group>
<award-group>
<funding-source id="cn002">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source>
<award-id rid="cn002">T32 GM008283-27</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="13"></fig-count>
<table-count count="2"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="174"></ref-count>
<page-count count="23"></page-count>
<word-count count="17117"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>G protein-coupled receptors (GPCRs), which form the largest protein superfamily of the vertebrate genome, play an important role in signal transduction by detecting extracellular stimuli and activating intracellular downstream pathways (Figure <xref ref-type="fig" rid="F1">1</xref>; Fredriksson et al., <xref ref-type="bibr" rid="B49">2003</xref>). All GPCRs share a common seven-transmembrane topology, and mediate cellular responses through interactions with a variety of extracellular signals. These extracellular signals range from photons and small molecules to hormones and proteins, indicating the structural and functional diversity of over 800 different GPCRs (Lagerstrom and Schioth, <xref ref-type="bibr" rid="B86">2008</xref>). Despite the diversity, GPCRs share a general mechanism of activation that begins with ligand binding, which causes conformational rearrangements in the seven-transmembrane (7TM) domain that activate the G protein in the cytoplasmic region. G protein activation triggers various signaling cascades to mediate physiological processes. Since the ligand binding sites are highly specific, GPCRs have been heavily exploited as drug targets. They are the targets for over 40% of the current pharmaceutical drugs on the market with an estimated global sales of ~$85 billion (Stevens et al., <xref ref-type="bibr" rid="B147">2013</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p><bold>A comparison of GPCRs in family B with GPCRs in the other four families</bold>. Family B GPCRs detect peptide hormones and have a relatively large extracellular N-terminus (~120 amino acids) with a conserved structural fold stabilized by cysteine bonds. Family A GPCRs bind a wide range of diverse ligands in the transmembrane region and have a small extracellular domain. Family C receptors have a large extracellular N-terminal ligand-binding region in the “Venus flytrap” fold for ligand binding with a conserved disulfide linkage to form a dimer. The adhesion and frizzled families have GPCR-like transmembrane-spanning regions fused together with one or several functional N-terminal domains. Ligands are shown in red. Scissors in the adhesion family indicate the autoproteolysis-inducing domain.</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0001"></graphic>
</fig>
<p>Although most drugs developed against GPCRs target family A receptors, family B GPCRs are becoming increasingly attractive drug targets, especially for treatment of metabolic diseases (Tautermann, <xref ref-type="bibr" rid="B152">2014</xref>). The 15 family B GPCRs for various peptide hormones are grouped into subfamilies based on their physiological roles, including insulin secretion, vasodilation, regulation of Ca<sup>2+</sup> homeostasis, and cardiac contractility (Table <xref ref-type="table" rid="T1">1</xref>). Nearly all family B GPCRs have been validated as drug targets for diseases, such as cancer, osteoporosis, diabetes, cardiovascular disease, neurodegeneration, and migraine (Table <xref ref-type="table" rid="T1">1</xref>; Archbold et al., <xref ref-type="bibr" rid="B4">2011</xref>). However, it has been challenging to identify small-molecule therapeutics to target this family, with only a few peptide agonists approved by the FDA as drugs. Most of these agonist drugs are derivatives of the family B cognate peptide ligands (Table <xref ref-type="table" rid="T1">1</xref>). The challenge of identifying conventional small-molecule drugs lies in the lack of molecular information to locate druggable binding sites for <italic>in silico</italic> drug design and screening. Nevertheless, the recently reported and first available crystal structures of the transmembrane domain (TMD) of two family B GPCRs are expected to advance the development (Hollenstein et al., <xref ref-type="bibr" rid="B70">2013</xref>; Siu et al., <xref ref-type="bibr" rid="B143">2013</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p><bold>Summary of Family B GPCR physiology and drugs (Hoare, <xref ref-type="bibr" rid="B66">2005</xref>; Archbold et al., <xref ref-type="bibr" rid="B4">2011</xref>; Bortolato et al., <xref ref-type="bibr" rid="B15">2014</xref>)</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Receptor(s)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Ligands</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Physiological functions</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Disease(s)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Available drugs</bold>
</th>
</tr>
</thead>
<tbody>
<tr style="border-top: thin solid #000000;">
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>CALCITONIN RECEPTOR FAMILY</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Calcitonin receptor (CTR)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Calcitonin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ca<sup>2+</sup> homeostasis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Osteoporosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Miacalcin, Fortical</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Amylin receptors (AMY<sub>1</sub>, AMY<sub>2</sub>, AMY<sub>3</sub>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Amylin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Energy homeostasis and body fluid balance</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diabetes/obesity</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pramlintide</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Amyloid-beta (Aβ) protein</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Calcitonin gene-related peptide receptor (CGRP receptor)</td>
<td align="left" colspan="1" rowspan="1" valign="top">α-calcitonin gene-related peptide (α-CGRP)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vasodilation and nociception</td>
<td align="left" colspan="1" rowspan="1" valign="top">Migraine</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">ß-CGRP</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Adrenomedullin receptors (AM<sub>1</sub>, AM<sub>2</sub>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">adrenomedullin 1</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vasodilation</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cardiovascular disease, cancer</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">adrenomedullin 2</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>GLUCAGON RECEPTOR FAMILY</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glucagon receptor (GCGR)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glucagon</td>
<td align="left" colspan="1" rowspan="1" valign="top">Regulation of blood glucose</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diabetes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glucagon</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glucagon-like peptide 1 receptor (GLP-1R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glucagon-like peptide 1 (GLP-1)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Insulin and glucagon secretion</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diabetes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exenatide, Lixisenatide, Liraglutide, Albiglutide, Dulaglutide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glucagon-like peptide 2 receptor (GLP-2R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glucagon-like peptide 2 (GLP-2)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gut mucosal growth</td>
<td align="left" colspan="1" rowspan="1" valign="top">Short bowel syndrome, Crohn's disease, osteoporosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Teduglutide</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Gastric inhibitory polypeptide receptor (GIPR)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Gastric inhibitory polypeptide (GIP)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Insulin secretion, fatty acid metabolism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diabetes/obesity</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>CORTICOTROPIN-RELEASING HORMONE RECEPTORS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Corticotropin-releasing factor receptor 1 (CRF1R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Corticotropin-releasing factor (CRF)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Release of ACTH and central stress responses</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stress, inflammatory bowel syndrome</td>
<td align="left" colspan="1" rowspan="1" valign="top">Corticorelin</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Urocortin I (Ucn1)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Corticotropin-releasing factor receptor 2 (CRF2R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CRF</td>
<td align="left" colspan="1" rowspan="1" valign="top">Central stress responses, cardiac contractility, hearing</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cancer, heart failure, hypertension</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Urocortin II (Ucn2)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Urocortin III (Ucn3)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>PARATHYROID HORMONE RECEPTORS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Parathyroid hormone 1 receptor (PTH1R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Parathyroid hormone (PTH)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ca<sup>2+</sup> homeostasis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Osteoporosis, hypoparathyroidism</td>
<td align="left" colspan="1" rowspan="1" valign="top">Teriparatide, Preotact</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Parathyroid hormone-related protein (PTHrP)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Developmental regulator</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Parathyroid hormone 2 receptor (PTH2R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PTH</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hypothalamic secretion, nociception</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nociception</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Tuberoinfundibular peptide of 39 residues (TIP39)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTORS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Vasoactive intestinal polypeptide receptor 1 (VPAC<sub>1</sub>R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vasoactive intestinal polypeptide (VIP)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vasodilation, neurotransmission, neuroendocrine functions</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inflammation, neurodegeneration</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PACAP</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Vasoactive intestinal polypeptide receptor 2 (VPAC<sub>2</sub>R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">VIP</td>
<td align="left" colspan="1" rowspan="1" valign="top">Vasodilation, neurotransmission neuroendocrine functions</td>
<td align="left" colspan="1" rowspan="1" valign="top">Inflammation, neurodegeneration</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">PACAP</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>OTHERS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1R)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pituitary adenylate cyclase-activating polypeptide (PACAP)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurotransmission neuroendocrine functions</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neurodegeneration nociception, glucose homeostasis</td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Growth-hormone-releasing hormone receptor (GHRHR)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Growth hormone-releasing hormone (GRHR)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Release of growth hormone</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dwarfism, HIV-related lipodystrophy</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tesamorelin, Sermorelin, CJC-1295</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Secretin receptor (SCTR)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Secretin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pancreatic secretion</td>
<td align="left" colspan="1" rowspan="1" valign="top">Autism, schizophrenia, duodenal ulcers, gastrinoma</td>
<td colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Compared to GPCRs in other families (Figure <xref ref-type="fig" rid="F1">1</xref>), family B GPCRs have a relatively large N-terminus that is ~120 amino acids long. Their N-terminus shares a similar fold stabilized by three conserved disulfide bridges, which construct part of the binding site for ligand recognition. While GPCRs in other families have a wide range of ligands, such as small molecules, ions, lipids, and proteins, all family B receptors bind peptide hormones, modulating physiological processes such as calcium homeostasis and regulation of blood glucose, as summarized in Table <xref ref-type="table" rid="T1">1</xref>.</p>
<p>Ligands that activate family B GPCRs are peptide hormones with a length of 26 to 114 amino acids. Most ligands of family B GPCRs lack ordered structure in aqueous solutions but form α-helical fragments upon binding to their cognate receptors or under structure-inducing conditions such as in the presence of organic solvents, lipids, or upon crystallization (as reviewed in Parthier et al., <xref ref-type="bibr" rid="B114">2009</xref>). It is widely accepted that the peptide hormones interact with family B GPCRs following the “two-domain” model, in which the peptide hormone's C-terminus binds to their cognate receptor's N-terminal domain and the N-terminus binds to the receptor's juxtamembrane and transmembrane domains (Figure <xref ref-type="fig" rid="F2">2</xref>). Such binding leads to conformational changes in the receptor's cytoplasmic domain to active a G protein to trigger a downstream signaling process (Pal et al., <xref ref-type="bibr" rid="B108">2012</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p><bold>Two-domain binding model of family B GPCRs</bold>. The C-terminal region of the peptide ligand interacts with the N-terminal domain of the receptor (yellow), allowing the N-terminus of the peptide ligand to interact with the juxtamembrane and TMD (red) to activate the receptor.</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0002"></graphic>
</fig>
<p>Tremendous progress has been made in the past 15 years to obtain structural information about GPCRs; however, knowledge about the structure of family B GPCRs is still very limited. Most of the previous structural studies of GPCRs focus on family A receptors, with over a hundred solved crystal structures of over 20 different receptors. For family B GPCRs, most efforts were focused on obtaining the crystal structures of the N-terminal ligand-binding domains (Grace et al., <xref ref-type="bibr" rid="B60">2007</xref>; Parthier et al., <xref ref-type="bibr" rid="B113">2007</xref>; Sun et al., <xref ref-type="bibr" rid="B148">2007</xref>; Pioszak and Xu, <xref ref-type="bibr" rid="B121">2008</xref>; Pioszak et al., <xref ref-type="bibr" rid="B120">2008</xref>, <xref ref-type="bibr" rid="B119">2009</xref>; Runge et al., <xref ref-type="bibr" rid="B133">2008</xref>; Pal et al., <xref ref-type="bibr" rid="B109">2010</xref>; Kumar et al., <xref ref-type="bibr" rid="B84">2011</xref>) until Hollenstein et al. and Siu et al. reported the crystal structures of transmembrane domain of two family B receptors in 2013 (Table <xref ref-type="table" rid="T2">2</xref>; Hollenstein et al., <xref ref-type="bibr" rid="B70">2013</xref>; Siu et al., <xref ref-type="bibr" rid="B143">2013</xref>). Although this structural information has provided insights into the structural and functional diversity of family B GPCRs, there is still no full-length structure of family B GPCRs available. Hence, how the extracellular ligand binding domain and transmembrane domain of family B GPCRs cooperate to transduce a signal across the cell membrane upon ligand binding remains largely unknown. Here, we will review the recent progress in addressing this question by surveying the structural, biochemical, and biophysical studies of various domains of family B GPCRs (Figure <xref ref-type="fig" rid="F3">3</xref>).</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p><bold>Structures (X-ray or NMR) available for family B GPCR domains</bold>.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Receptor(s)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Domain</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>PDB ID</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Ligand used</bold>
</th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>Resolution (Å)</bold>
</th>
</tr>
</thead>
<tbody>
<tr style="border-top: thin solid #000000;">
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>CALCITONIN RECEPTOR FAMILY</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CGRP receptor (ter Haar et al., <xref ref-type="bibr" rid="B154">2010</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD complex (CLR 23–133 + RAMP1 26–117)</td>
<td align="left" colspan="1" rowspan="1" valign="top">3N7P</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.80</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD complex (CLR 23–133 + RAMP1 26–117)</td>
<td align="left" colspan="1" rowspan="1" valign="top">3N7R</td>
<td align="left" colspan="1" rowspan="1" valign="top">telcagepant (a small molecule antagonist)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.90</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD complex (CLR 23–133 + RAMP1 26–117)</td>
<td align="left" colspan="1" rowspan="1" valign="top">3N7S</td>
<td align="left" colspan="1" rowspan="1" valign="top">olcegepant (a small molecule antagonist)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.10</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">AM1 receptor (Kusano et al., <xref ref-type="bibr" rid="B85">2012</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD complex (CLR 23–136 + RAMP2 39–139)</td>
<td align="left" colspan="1" rowspan="1" valign="top">3AQF</td>
<td align="left" colspan="1" rowspan="1" valign="top">No ligand</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.60</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>GLUCAGON RECEPTOR FAMILY</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Glucagon receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 28–123</td>
<td align="left" colspan="1" rowspan="1" valign="top">4ERS (Koth et al., <xref ref-type="bibr" rid="B83">2012</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">No ligand</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.64</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 29–123</td>
<td align="left" colspan="1" rowspan="1" valign="top">4LF3 (Mukund et al., <xref ref-type="bibr" rid="B102">2013</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">No ligand</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.73</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TMD 123–434</td>
<td align="left" colspan="1" rowspan="1" valign="top">4L6R (Siu et al., <xref ref-type="bibr" rid="B143">2013</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="center" colspan="1" rowspan="1" valign="top">3.30</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GLP-1R</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 24–145</td>
<td align="left" colspan="1" rowspan="1" valign="top">3IOL (Underwood et al., <xref ref-type="bibr" rid="B157">2010</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">GLP-1(7–37)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.10</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD complex 24–145</td>
<td align="left" colspan="1" rowspan="1" valign="top">3C5T (Runge et al., <xref ref-type="bibr" rid="B133">2008</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Exendin-4(9–39)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.10</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 24–145</td>
<td align="left" colspan="1" rowspan="1" valign="top">3C59 (Runge et al., <xref ref-type="bibr" rid="B133">2008</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">(SeMet14,21)-exendin-4(9–39)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.30</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GIPR</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 24–138</td>
<td align="left" colspan="1" rowspan="1" valign="top">4HJ0 (Ravn et al., <xref ref-type="bibr" rid="B128">2013</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antibody</td>
<td align="center" colspan="1" rowspan="1" valign="top">3.00</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 29–138</td>
<td align="left" colspan="1" rowspan="1" valign="top">2QKH (Parthier et al., <xref ref-type="bibr" rid="B113">2007</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">GIP (1–42)</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.90</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>CORTICOTROPIN-RELEASING HORMONE RECEPTORS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CRF1R</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 24–119</td>
<td align="left" colspan="1" rowspan="1" valign="top">3EHS (Pioszak et al., <xref ref-type="bibr" rid="B120">2008</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.76</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 24–119</td>
<td align="left" colspan="1" rowspan="1" valign="top">3EHT (Pioszak et al., <xref ref-type="bibr" rid="B120">2008</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CRF27–41</td>
<td align="center" colspan="1" rowspan="1" valign="top">3.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 24–119</td>
<td align="left" colspan="1" rowspan="1" valign="top">3EHU (Pioszak et al., <xref ref-type="bibr" rid="B120">2008</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CRF22–41</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.96</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">TMD 104–373</td>
<td align="left" colspan="1" rowspan="1" valign="top">4K5Y (Hollenstein et al., <xref ref-type="bibr" rid="B70">2013</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antagonist: CP-376395 (small molecule)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.98</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CRFR2α</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 3–154</td>
<td align="left" colspan="1" rowspan="1" valign="top">3N96 (Pal et al., <xref ref-type="bibr" rid="B109">2010</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Urocortin-1 (25–40)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.75</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 3–154</td>
<td align="left" colspan="1" rowspan="1" valign="top">3N95 (Pal et al., <xref ref-type="bibr" rid="B109">2010</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Urocortin-2 (23–38)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.72</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 3–154</td>
<td align="left" colspan="1" rowspan="1" valign="top">3N93 (Pal et al., <xref ref-type="bibr" rid="B109">2010</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Urocortin-3 (23–38)</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.50</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CRFR-2β</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 15–133</td>
<td align="left" colspan="1" rowspan="1" valign="top">1U34 (Grace et al., <xref ref-type="bibr" rid="B59">2004</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="center" colspan="1" rowspan="1" valign="top">N/A NMR</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 39–133</td>
<td align="left" colspan="1" rowspan="1" valign="top">2JNC (Grace et al., <xref ref-type="bibr" rid="B60">2007</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">No ligand</td>
<td align="center" colspan="1" rowspan="1" valign="top">N/A NMR</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 39–133</td>
<td align="left" colspan="1" rowspan="1" valign="top">2JND (Grace et al., <xref ref-type="bibr" rid="B60">2007</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Astressin</td>
<td align="center" colspan="1" rowspan="1" valign="top">N/A NMR</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>PARATHYROID HORMONE RECEPTORS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PTH1R</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 29–187</td>
<td align="left" colspan="1" rowspan="1" valign="top">3L2J (Pioszak et al., <xref ref-type="bibr" rid="B118">2010</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="center" colspan="1" rowspan="1" valign="top">3.24</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 29–187</td>
<td align="left" colspan="1" rowspan="1" valign="top">3C4M (Pioszak and Xu, <xref ref-type="bibr" rid="B121">2008</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PTH(15–34)</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.95</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 29–187</td>
<td align="left" colspan="1" rowspan="1" valign="top">3H3G (Pioszak et al., <xref ref-type="bibr" rid="B119">2009</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PTHrP(12–34)</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.94</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTORS</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">VIP2R</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 26–118</td>
<td align="left" colspan="1" rowspan="1" valign="top">2X57</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="center" colspan="1" rowspan="1" valign="top">2.10</td>
</tr>
<tr>
<td align="left" colspan="5" rowspan="1" style="background-color:#bbbdc0" valign="top">
<bold>Others</bold>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PACAP receptor</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 22–143</td>
<td align="left" colspan="1" rowspan="1" valign="top">2JOD (Sun et al., <xref ref-type="bibr" rid="B148">2007</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PACAP (6–38)</td>
<td align="center" colspan="1" rowspan="1" valign="top">N/A NMR</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD</td>
<td align="left" colspan="1" rowspan="1" valign="top">3N94 (Kumar et al., <xref ref-type="bibr" rid="B84">2011</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PACAP (6–38)</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.80</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GHRHR</td>
<td align="left" colspan="1" rowspan="1" valign="top">N-terminal LBD 34–123</td>
<td align="left" colspan="1" rowspan="1" valign="top">2XDG</td>
<td align="left" colspan="1" rowspan="1" valign="top">N/A</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.95</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p><bold>Structural model for family B GPCRs</bold>. Three domains in family B GPCRs: (1) the extracellular domain, comprising of the N-terminal domain and the juxtamembrane domain, (2) the transmembrane domain (TMD), and (3) the cytoplasmic domain. Three accessory proteins: (1) receptor activity modifying proteins (RAMPs), (2) Na/H exchange regulatory factors (NHERFs), (3) calmodulin (CaM). Purple: a family B GPCR, yellow: three conserved disulfide bonds, blue: a heterotrimeric G protein, and red: accessory proteins.</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0003"></graphic>
</fig>
<p>In this review, we will focus on how the extracellular, transmembrane, and cytoplasmic domains of family B GPCRs (Figure <xref ref-type="fig" rid="F3">3</xref>) carry out the functions of peptide hormone recognition and signal transduction across the cell membrane. We will also discuss how this signaling process is modulated by accessory proteins (Figure <xref ref-type="fig" rid="F3">3</xref>). On the basis of the two-domain model (Figure <xref ref-type="fig" rid="F3">3</xref>), we will first discuss the recognition and binding of peptide ligands in the extracellular domains, including the N-terminal and juxtamembrane domains (Section Extracellular Domain: Ligand Binding). Then, we will discuss ligand interactions and ligand-induced helical movements in the transmembrane domain (Section Transmembrane Domain: Ligand-induced Helical Movements). Subsequently, we will review how activated family B GPCRs couple to G proteins in cytoplasmic domain (Section Cytoplasmic Domain: G Protein Coupling). We will also provide a brief overview of accessory proteins that regulate the activity of family B GPCRs (Section Interaction with Accessory Proteins). Finally, we will conclude with a summary and outlook of mechanistic studies of family B GPCRs (Section Challenges and Outlook). Through these discussions, we hope to provide a systematic review of the current understanding of molecular activation mechanism of family B GPCRs.</p>
</sec>
<sec id="s2">
<title>Extracellular domain: ligand binding</title>
<p>The extracellular domain of family B GPCRs contains two parts: the N-terminal domain and the juxtamembrane domain (Figure <xref ref-type="fig" rid="F3">3</xref>). The latter is composed of three extracellular loops and the peptide fragment at the junction between the N-terminal domain and helix 1. The N-terminal and juxtamembrane domains work together to sense the peptide hormones in the initial step of signal transduction. Solved structures of the extracellular domains bound to their cognate peptide ligands (Table <xref ref-type="table" rid="T2">2</xref>) provide crucial information about mechanisms of ligand recognition and selectivity. In this section, we will first discuss the two-domain binding model and then the specific molecular interactions of the ligands with the N-terminal and juxtamembrane domains of the receptors.</p>
<sec>
<title>Experimental evidence for the two-domain binding model</title>
<p>The two-domain binding model, as described in Figure <xref ref-type="fig" rid="F2">2</xref>, has been widely used to describe the binding of peptide hormones to family B GPCRs (as reviewed in Pal et al., <xref ref-type="bibr" rid="B108">2012</xref>), which is supported by kinetic and reciprocal chimera studies.</p>
<p>In the kinetic studies, Förster Resonance Energy Transfer (FRET) experiments of parathyroid hormone (PTH) binding to parathyroid hormone receptor 1 (PTH1R) showed the first high affinity binding step occurs quickly (~0.10 s) and the second activation step slowly (~1 s) (Vilardaga et al., <xref ref-type="bibr" rid="B160">2011</xref>). Although similar kinetic data from other members of the family is currently unknown, the two-step kinetics of receptor binding and activation may potentially be conserved in other family B GPCRs.</p>
<p>The two-domain model is also supported by two representative chimera studies, in which one GPCR is created from pieces of two different receptors and one ligand from pieces of the two corresponding cognate peptide ligands (Figure <xref ref-type="fig" rid="F4">4A</xref>). In the first study, Bergwitz et al. designed a chimeric system using calcitonin receptor (CTR) and PTH1R, and determined the activation of the chimeric receptors by quantifying cAMP accumulation after treatment with two chimeric peptide hormones (Bergwitz et al., <xref ref-type="bibr" rid="B14">1996</xref>). The chimeric peptide hormones with calcitonin at the C-terminus most strongly activated the chimeric receptor with CTR's N-terminal domain. Similarly, the peptide ligand with the PTH C-terminus most strongly activated the chimeric receptor with the PTH1R's N-terminal domain (Bergwitz et al., <xref ref-type="bibr" rid="B14">1996</xref>). In the second study, Unson et al. mutated regions of the N-terminal domain and juxtamembrane domain of the glucagon receptor (GCGR) to the corresponding regions of the secretin receptor (SCTR, Figure <xref ref-type="fig" rid="F4">4B</xref>; Unson et al., <xref ref-type="bibr" rid="B158">2002</xref>). Chimeric receptors containing secretin residues for the N-terminal domain residues 126–137 or the extracellular loop 1 residues 206–219 showed the largest decrease in both ligand binding and receptor activation upon binding to the glucagon peptide (Figure <xref ref-type="fig" rid="F4">4B</xref>). Interestingly, a chimeric GCGR/SCTR with SCTR residues in extracellular loop 1 residues 220–231 showed no change in binding affinity to the glucagon peptide, but a decrease in receptor activation (Unson et al., <xref ref-type="bibr" rid="B158">2002</xref>), further elucidating a specific region of the juxtamembrane domain involved in the second binding step and receptor activation, supporting the two-domain model.</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p><bold>Ligand interactions with the juxtamembrane domain</bold>. <bold>(A)</bold> General chimeric receptor made from components of two receptors: one receptor's extracellular domain and C-terminus of the ligand (teal) and the other receptor's transmembrane domain and N-terminus of the ligand (purple). <bold>(B)</bold> Binding studies of a chimeric GCGR (purple) with regions of SCTR (teal) implicate extracellular loop 1 and the middle region of the N-terminal domain in high affinity ligand binding (Bergwitz et al., <xref ref-type="bibr" rid="B14">1996</xref>; Unson et al., <xref ref-type="bibr" rid="B158">2002</xref>). <bold>(C)</bold> Photoaffinity cross-linking studies with Bpa show interactions between colored regions of secretin and the corresponding colored portion of SCTR. the long N-terminal fragment of secretin interacts deep in the transmembrane region of SCTR (Dong et al., <xref ref-type="bibr" rid="B42">2002</xref>, <xref ref-type="bibr" rid="B39">2004</xref>, <xref ref-type="bibr" rid="B37">2008</xref>, <xref ref-type="bibr" rid="B38">2011b</xref>, <xref ref-type="bibr" rid="B41">2012</xref>). <bold>(D)</bold> Interactions between VIP and VPAC<sub>1</sub>R as determined by mutations and photoaffinity cross-linking studies show similar interaction regions as secretin/SCTR (Couvineau et al., <xref ref-type="bibr" rid="B27">1995</xref>; Du et al., <xref ref-type="bibr" rid="B44">1997</xref>; Tan et al., <xref ref-type="bibr" rid="B151">2003</xref>, <xref ref-type="bibr" rid="B150">2006</xref>; Ceraudo et al., <xref ref-type="bibr" rid="B19">2008</xref>).</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0004"></graphic>
</fig>
</sec>
<sec>
<title>Ligand binding interactions with the N-terminal domain</title>
<p>The first step in the two-domain model—ligand binding to the N-terminus of receptors—is strongly supported by crystal structures of nine different ligands bound to the N-terminal domain of their respective receptors (Table <xref ref-type="table" rid="T2">2</xref> and Figure <xref ref-type="fig" rid="F5">5</xref>; Grace et al., <xref ref-type="bibr" rid="B59">2004</xref>; Parthier et al., <xref ref-type="bibr" rid="B113">2007</xref>; Sun et al., <xref ref-type="bibr" rid="B148">2007</xref>; Pioszak and Xu, <xref ref-type="bibr" rid="B121">2008</xref>; Pioszak et al., <xref ref-type="bibr" rid="B120">2008</xref>, <xref ref-type="bibr" rid="B119">2009</xref>; ter Haar et al., <xref ref-type="bibr" rid="B154">2010</xref>; Underwood et al., <xref ref-type="bibr" rid="B157">2010</xref>; Koth et al., <xref ref-type="bibr" rid="B83">2012</xref>). These crystal structures reveal that the N-terminal domains contain a conserved three-layered α-β-βα fold (Figure <xref ref-type="fig" rid="F6">6</xref>) with the helical segment of the peptide hormone primarily interacting in the middle layer as if a “hotdog in a bun” (Figures <xref ref-type="fig" rid="F5">5A–C</xref>, <xref ref-type="fig" rid="F6">6</xref>) (Parthier et al., <xref ref-type="bibr" rid="B114">2009</xref>; Pal et al., <xref ref-type="bibr" rid="B108">2012</xref>). Six conserved cysteine residues form three interlayer disulfide bonds that stabilize the α-β-β α fold (Figure <xref ref-type="fig" rid="F6">6</xref>). Additional hydrophobic packing interactions and hydrogen bonds stabilize the second and third layers (as reviewed in Hollenstein et al., <xref ref-type="bibr" rid="B69">2014</xref>). Sequence conservation indicates the importance of these stabilizing interactions, which likely involve five mostly conserved residues: Asp113, Trp118, Pro132 and Gly152, and Trp154 (PTH1R residues, pink in Figures <xref ref-type="fig" rid="F6">6A,B</xref>; Pioszak and Xu, <xref ref-type="bibr" rid="B121">2008</xref>). These conserved residues and the structural similarities of the three-layered fold form a structural foundation for the two-domain binding model.</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p><bold>Available crystal structures of the N-terminal domains of nine family B GPCRs</bold>. <bold>(A)</bold> GLP-1 bound to GLP1R (Underwood et al., <xref ref-type="bibr" rid="B157">2010</xref>). <bold>(B)</bold> PTH bound to PTH1R (Pioszak and Xu, <xref ref-type="bibr" rid="B121">2008</xref>). <bold>(C)</bold> GIP bound to GIPR (Parthier et al., <xref ref-type="bibr" rid="B113">2007</xref>). <bold>(D)</bold> CRF bound to CRF1R (Pioszak et al., <xref ref-type="bibr" rid="B120">2008</xref>). <bold>(E)</bold> Astressin bound to CRF2R (Grace et al., <xref ref-type="bibr" rid="B59">2004</xref>). <bold>(F)</bold> PACAP bound to PACAPR (Sun et al., <xref ref-type="bibr" rid="B148">2007</xref>). <bold>(G)</bold> VPAC2R (PDB ID 2X57). <bold>(H)</bold> GCGR (Koth et al., <xref ref-type="bibr" rid="B83">2012</xref>). <bold>(I)</bold> CLR (ter Haar et al., <xref ref-type="bibr" rid="B154">2010</xref>).</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0005"></graphic>
</fig>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<p><bold>The three-layered α-β-βα fold for the N-terminal domain of family B GPCRs</bold>. <bold>(A)</bold> Schematic of the α-β-βα fold with conserved residues (pink) and disulfide bonds (yellow). <bold>(B)</bold> A representative crystal structure showing the α-β-βα fold, disulfide bonds and conserved residues (PDB 2QKH Parthier et al., <xref ref-type="bibr" rid="B113">2007</xref>). <bold>(C,D)</bold> Important residues in peptide ligands for binding to PTH1R <bold>(C)</bold> and GIPR <bold>(D)</bold> identified by crystal contacts and mutagenesis studies. Important residues contacts are shown as sticks. Color codes: the top (red), middle (green), and bottom (blue) layers, three conserved disulfide bonds (yellow), conserved residues stabilizing the three-layer fold (pink), ligand residues important in binding affinity (orange; Pioszak and Xu, <xref ref-type="bibr" rid="B121">2008</xref>).</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0006"></graphic>
</fig>
<p>However, there are a few differences between the structures of the various receptor N-terminal domains, which likely provide ligand specificity. For example, Grace et al. determined the structure of the N-terminal domain of CRF2R (Figure <xref ref-type="fig" rid="F5">5E</xref>) using NMR and found the absence of the N-terminal α-helix that is conserved in the majority of the other crystal structures (Figure <xref ref-type="fig" rid="F5">5</xref>; Grace et al., <xref ref-type="bibr" rid="B59">2004</xref>). More recent crystal structures of the N-terminal domains of CRF1R show the N-terminal α-helix tends to be shorter than the same region in other family B receptors (Figure <xref ref-type="fig" rid="F5">5D</xref> compared to Figures <xref ref-type="fig" rid="F6">5A–C,F–I</xref>; Pioszak et al., <xref ref-type="bibr" rid="B120">2008</xref>). These structural characteristics cause the peptide hormone to interact with the N-terminal domain at a slightly shifted location compared to the other receptors including GLP-1R, PTH1R, and GIPR (Figures <xref ref-type="fig" rid="F5">5D,F</xref> compared to Figures <xref ref-type="fig" rid="F5">5A–C</xref>). Sequence alignment of the 15 Family B GPCRs supports the difference in the structure of the N-terminal α-helix as it shows a limited number of conserved residues in addition to the six conserved cysteine residues in the N-terminal domain (Pioszak et al., <xref ref-type="bibr" rid="B119">2009</xref>).</p>
<p>Aside from structural data, biochemical studies further support the two-domain binding model (summarized in Supplementary Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>). The reciprocal chimera studies that support the “hotdog in a bun” model also implicate the middle layer of the N-terminal domain in peptide hormone binding (Bergwitz et al., <xref ref-type="bibr" rid="B14">1996</xref>). In addition, results from alanine scanning studies further determined the N-terminal domain residues necessary for ligand binding (Barwell et al., <xref ref-type="bibr" rid="B12">2010</xref>). These alanine-scanning studies test receptor constructs with mutations in specific regions of a receptor for ligand binding affinity using radiolabeled ligands and for receptor activation using cell based cAMP accumulation assays. Depending on the location of the mutations, they might affect only the ligand binding affinity (the first binding event), only the receptor activation (the second binding event), or both responses. For example, mutations in the N-terminal α-helix (red in Figure <xref ref-type="fig" rid="F6">6A</xref>) of the calcitonin gene related peptide (CGRP) receptor show that mutating Leu32 and Leu34 to alanine decreases binding affinity (the first binding event) without decreasing cAMP production (the second binding event; Banerjee et al., <xref ref-type="bibr" rid="B9">2006</xref>).</p>
<p>A complementary approach to uncovering the ligand binding determinants involves alanine scanning of the peptide hormone residues (Adelhorst et al., <xref ref-type="bibr" rid="B1">1994</xref>; Nicole et al., <xref ref-type="bibr" rid="B104">2000</xref>; Igarashi et al., <xref ref-type="bibr" rid="B72">2002a</xref>,<xref ref-type="bibr" rid="B73">b</xref>; Bourgault et al., <xref ref-type="bibr" rid="B16">2009</xref>; Dong et al., <xref ref-type="bibr" rid="B38">2011b</xref>, <xref ref-type="bibr" rid="B40">2013</xref>; Watkins et al., <xref ref-type="bibr" rid="B164">2013</xref>). Figure <xref ref-type="fig" rid="F6">6</xref> shows important results from alanine scanning studies of PTH and gastric inhibitory polypeptide (GIP). The residues labeled in orange in the peptide hormones significantly decrease binding affinity when mutated to alanine, confirming their importance in ligand binding (Parthier et al., <xref ref-type="bibr" rid="B113">2007</xref>; Pioszak and Xu, <xref ref-type="bibr" rid="B121">2008</xref>). In addition, one recent study of the secretin peptide with ligand binding and activation assays compared results from five receptors and found many N-terminal residues of the hormones are important for both ligand binding and biological activity, while C terminal residues tend to be important for binding affinity (Figure <xref ref-type="fig" rid="F7">7</xref>; Dong et al., <xref ref-type="bibr" rid="B38">2011b</xref>). In combination with the crystal structures and N-terminal domain mutations, this provides a more complete view of the high affinity binding of the C-terminal region of the peptide to the N-terminal domain, the first step of the two-domain binding model.</p>
<fig id="F7" position="float">
<label>Figure 7</label>
<caption>
<p><bold>Structure based alignment of family B GPCR ligands from the center of the α-helix (red)</bold>. The blue and green lines show residues that decrease ligand-binding affinity when mutated. Blue lines indicate mutations that decrease ligand binding without specifying the region of the receptor where the interaction occurs. Green lines indicate residues implicated in ligand binding that interact with the N-terminal domain as confirmed by crystal structures. The data for the calcitonin receptor comes from cross-linking experiments (Adelhorst et al., <xref ref-type="bibr" rid="B1">1994</xref>; Igarashi et al., <xref ref-type="bibr" rid="B73">2002b</xref>; Perret et al., <xref ref-type="bibr" rid="B115">2002</xref>; Dong et al., <xref ref-type="bibr" rid="B39">2004</xref>; Pham et al., <xref ref-type="bibr" rid="B117">2004</xref>, <xref ref-type="bibr" rid="B116">2005</xref>; Parthier et al., <xref ref-type="bibr" rid="B113">2007</xref>; Sun et al., <xref ref-type="bibr" rid="B148">2007</xref>; Pioszak and Xu, <xref ref-type="bibr" rid="B121">2008</xref>; Pioszak et al., <xref ref-type="bibr" rid="B120">2008</xref>, <xref ref-type="bibr" rid="B119">2009</xref>; Bourgault et al., <xref ref-type="bibr" rid="B16">2009</xref>).</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0007"></graphic>
</fig>
</sec>
<sec>
<title>Ligand binding to the juxtamembrane domain</title>
<p>The second step of the two-domain binding model involves interactions between the N-terminus of the peptide and the juxtamembrane domain of the receptor, which has been less studied mainly due to the lack of structural information of full-length family B GPCRs. Photoaffinity cross-linking has been commonly used to probe these interactions and elucidate specific contacts between the peptide ligand and the receptor. In the photoaffinity studies, <italic>p</italic>-benzoyl-L-phenylalanine (Bpa) is incorporated in the hormone ligands as a probe. Upon exposure to UV light, the Bpa residue is cross-linked with the residues in the receptor within 9 Å. Hence, the site of interaction can then be determined by proteolytic Edman degradation followed by autoradiography (Miller et al., <xref ref-type="bibr" rid="B99">2011</xref>). Photoaffinity studies on GLP-1R, SCTR, and PTH1R have identified important receptor/ligand interactions (Figure <xref ref-type="fig" rid="F4">4</xref>; Zhou et al., <xref ref-type="bibr" rid="B173">1997</xref>; Chen et al., <xref ref-type="bibr" rid="B20">2009</xref>; Dong et al., <xref ref-type="bibr" rid="B36">2011a</xref>; Miller et al., <xref ref-type="bibr" rid="B99">2011</xref>). For example, Dong et al. investigated secretin/SCTR interactions, with five different Bpa label positions and found the labels at the C-terminal end of the peptide (residues 15, 20, 24, 25) interacted with the N-terminal domain (blue, Figure <xref ref-type="fig" rid="F4">4C</xref>), while labels at the N-terminus of the peptide interact with extracellular loop 1 and regions of the transmembrane domain (red, Figure <xref ref-type="fig" rid="F4">4C</xref>; Dong et al., <xref ref-type="bibr" rid="B36">2011a</xref>). The interactions identified support the second step of the N-terminal region of the ligand interacting with the juxtamembrane domain in the two-domain binding model.</p>
<p>Moreover, mutagenesis studies of the extracellular loops of receptors also show the importance of the juxtamembrane domain in ligand binding and receptor activation. For instance, Gkountelias et al. studied CRF1R. They mutated residues in all three of the extracellular loops and found that two mutations in extracellular loop 2 (Phe260 and Trp259) decreased both ligand binding affinity and receptor activation (Gkountelias et al., <xref ref-type="bibr" rid="B58">2009</xref>). In addition, an alanine scanning study of the calcitonin receptor implicated extracellular loop 1 in ligand binding (Barwell et al., <xref ref-type="bibr" rid="B11">2011</xref>). These results suggest that the juxtamembrane domain is involved in not only ligand binding but also receptor activation in the two-domain binding model.</p>
<p>A final important factor in ligand binding to the juxtamembrane domain is the structure of the N-terminal region of the peptide hormone. By analyzing the sequence of the N-terminal region of the peptide ligands, Neumann et al. identified conserved helix-capping motifs, which provide additional hydrogen bonds for stabilizing the configuration of the first four amino acids in the α-helices (Neumann et al., <xref ref-type="bibr" rid="B103">2008</xref>). Based on the analysis, they proposed that this helix-capping can play an important role in receptor specificity and formation of α-helix in the peptide ligands upon binding to receptors (Parthier et al., <xref ref-type="bibr" rid="B114">2009</xref>). These proposed functional roles of the helix-capping motifs may be very important and are worth further experimental validation.</p>
<p>Aside from specific interactions between the peptide hormone and the extracellular domain, other factors influence ligand binding affinity and specificity for a given receptor. One such situation occurs when a receptor binds more than one native ligand, with each ligand eliciting a distinct physiological response. For instance, PTH1R interacts with two native ligands, PTH and PTHrP. While both peptides initiate cAMP accumulation inside cells, continuous administration of individual ligands induces opposite physiological effects, with PTH increasing bone resorption and PTHrP stimulating bone formation (Mannstadt et al., <xref ref-type="bibr" rid="B96">1999</xref>). Nonetheless, how the receptors distinguish between these different pathways remains unclear. In addition, allosteric effects from regions of the receptors not directly involved in ligand binding add complexity to the molecular mechanism of ligand recognition in family B GPCRs. For example in GLP-1R, a mutation across the membrane in intracellular loop 3 (ICL3) decreases the binding affinity of the GLP-1 ligand by 10-fold (Heller et al., <xref ref-type="bibr" rid="B64">1996</xref>). Further investigation into allosteric effects is likely to uncover new mechanisms of ligand selectivity in family B GPCRs.</p>
<p>Both structural and biochemical results greatly increase the understanding of the interactions of the peptide hormone binding to the N-terminal and juxtamembrane domains, formulating the well accepted two-domain binding model. Although the process of peptide-hormone binding to the receptor is the most studied event of the signaling cascades, identifying interactions is only part of the story. Very little is known about how those interactions cause conformational changes that propagate the signal to the cytoplasmic side of the receptor, resulting in activation of G proteins. In the following section, we will summarize the current understanding of such conformational changes in the transmembrane region of family B GPCRs.</p>
</sec>
</sec>
<sec id="s3">
<title>Transmembrane domain: ligand-induced helical movements</title>
<p>The transmembrane domain (TMD) of family B GPCRs serves as the bridge for communication between extracellular ligand binding and the G-protein coupling at cytoplasmic regions. Ligand binding causes conformational rearrangements within the TMD, which triggers downstream signaling cascades via G protein activation. The structures of the ligand-bound N-terminal domain of many family B GPCRs have been reported. In 2013, TMD crystal structures of two family B GPCRs were published, (Hollenstein et al., <xref ref-type="bibr" rid="B70">2013</xref>; Siu et al., <xref ref-type="bibr" rid="B143">2013</xref>) a major step forward in the field. However, the structure of a full-length family B GPCR remains largely unknown. As a result, the mechanistic understanding of conformational rearrangements in the activation process of family B GPCRs had long been stagnant. In this section, we will analyze the TMD structures of two family B GPCRs in comparison to family A GPCRs. We will focus on the ligand interactions within the TMD regions, as well as the potential of designing small-molecule modulators for binding to the TMD region of family B GPCRs. Finally, we will evaluate possible conformational changes of the TMD upon activation in light of both the new structural information and prior biochemical studies.</p>
<sec>
<title>Structural comparison of CRF1R and GCGR and key residues involved</title>
<p>To date, crystal structures of the TMD of two family B GPCRs are available. They include human corticotropin-releasing factor receptor 1 (CRF1R) in complex with the small-molecule antagonist CP-376395 at 3.0 Å resolution, (Hollenstein et al., <xref ref-type="bibr" rid="B70">2013</xref>) and human glucagon receptor (GCGR) in complex with the antagonist NNC0640 at 3.4 Å resolution crystalized with apocytochrome <italic>b562</italic>RIL from <italic>E.coli</italic> fused at the N-terminus (Siu et al., <xref ref-type="bibr" rid="B143">2013</xref>). CRF1R and GCGR share about 30% sequence identity within the TMD (Figure <xref ref-type="fig" rid="F8">8</xref>). Here, we compare their structural characteristics with respect to family A GPCRs.</p>
<fig id="F8" position="float">
<label>Figure 8</label>
<caption>
<p><bold>Structural-based sequence alignment of the transmembrane helices and helix 8 of family B GPCRs</bold>. For every position in the transmembrane region, the most conserved residue is color coded with its percent consensus (color coded from cyan 20% to red 100% consensus). The residues in transmembrane helices are numbered according to Wootten numbering scheme (Box 1 in Figure <xref ref-type="fig" rid="F10">10</xref>).</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0008"></graphic>
</fig>
<p>As expected, the hallmark 7TM helical bundles of family A GPCRs are observed in both CRF1R and GCGR. Figure <xref ref-type="fig" rid="F9">9</xref> presents the superimposition of the crystal structures of the 7TM of the two family B GPCRs and a representative family A GPCR [dopamine D<sub>3</sub> receptor (Chien et al., <xref ref-type="bibr" rid="B22">2010</xref>)] in their inactive conformations. While the structural conservation in the two family B GPCRs appears highest among the cytoplasmic half of TM helices, the extracellular half shows more divergence. This suggests each receptor has a characteristic, highly selective ligand-binding site. Also, it is worth noting that GCGR has an extended, long TM1 as compared to family A GPCRs, which is seen in the sequence of most family B GPCRs (Figure <xref ref-type="fig" rid="F8">8</xref>). This helical fragment, extending into the extracellular and juxtamembrane domains, may play an important role in ligand binding and signal transduction of the transmembrane region. On the other hand, the structural similarity of the cytoplasmic half of the helices suggests conformational rearrangements associated with G protein binding upon activation may be more conserved because a large number of GPCRs interact with the same, less diverse G proteins. The TMD structures of the two family B GPCRs show that the extracellular sides of the transmembrane domains assume a “V” shape that is more open toward the extracellular side than any of the family A GPCR structures (Figure <xref ref-type="fig" rid="F9">9</xref>). The “V” shape conformation presents a large, solvent-filled cavity accessible to extracellular ligand binding. One side of the “V” shape is formed by TM1, TM6, and TM7, and the other side is by TM2–TM5 (Figure <xref ref-type="fig" rid="F9">9A</xref>). These bundles of helices are similar to those observed in rhodopsin and other family A receptors (Crocker et al., <xref ref-type="bibr" rid="B29">2006</xref>).</p>
<fig id="F9" position="float">
<label>Figure 9</label>
<caption>
<p><bold>Structural alignment of CRF<sub>1</sub> (gold, PDB ID 4K5Y) and GPCR (blue, PDB ID 4L6R)</bold>. <bold>(A)</bold> The receptors are viewed from two different angles from within the membrane. The TM helices are labeled and comprise the two halves of the V-shape open configuration. <bold>(B)</bold> Structural comparison of the two family B GPCRs with a family A GPCR, dopamine D<sub>3</sub> receptor (gray, PDB ID 3PBL), in its inactive form. Individual TM helices are shown after superposition of the three receptors.</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0009"></graphic>
</fig>
<p>Turning to TM1, TM6, and TM7 on one side of the “V” shape, TM6 and TM7 of both receptors point away from the center of the helical bundle. In CRF1R, this region is even further away from the center of the helical bundle compared to GCGR. Similar interhelical interactions in CRF1R and GCGR contribute to the stabilization of the extracellular half of the transmembrane domain. In CRF1R, TM1 packs against and stabilizes a kink in TM7 at Gly356<sup>7.50b∕7.46</sup> (Figure <xref ref-type="fig" rid="F10">10</xref> Box 1) through formation of hydrogen bonds between highly conserved Ser130<sup>1.50b∕1.46</sup> on TM1 and Phe357<sup>7.51b∕7.47</sup> and Ser353<sup>7.47b∕7.43</sup> on TM7 (Figure <xref ref-type="fig" rid="F10">10B</xref>). Although the same interaction is not clearly observed in the crystal structure of GCGR, the conserved residues Ser152<sup>1.50b∕1.46</sup> on TM1 and Gly393<sup>7.50b∕7.46</sup> on TM7 may perform a similar role, resulting in the kinked structure in TM7 that causes the extracellular halves of TM6 and TM7 to tilt away. The kink in TM7 is similar to the one revealed in the crystal structures of family A GPCRs situated at the highly conserved NPxxY motif. In addition, the TM6 and TM7 regions of both receptors exhibit high temperature factors, indicating structural flexibility and possible movements upon ligand binding and activation.</p>
<fig id="F10" position="float">
<label>Figure 10</label>
<caption>
<p><bold>Structural features of family B GPCRs</bold>. Conserved structural features in CRF1R (yellow) and GCGR (blue) are highlighted within the superposition of the two structures. <bold>(A)</bold> The receptors viewed from the extracellular side; <bold>(B,C)</bold> The conserved CRF1R and GCGR residues involved in TM1-7 and 2-3-4 interface interactions at the extracellular half of the V-shape open configuration; <bold>(D,E)</bold>. The conserved residues involved in TM2-3 and 3-6-7 interactions at the intracellular half of the V-shape configuration; <bold>(F)</bold> GCGR residues Glu 406 of H8 forms an ionic network interacting with TM2 and TM6. Polar contacts are indicated by red (CRF1R) or black (GCGR) dashes.</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0010"></graphic>
</fig>
<p>On the other side of the “V” shape, TM4 in both receptors contains the highly conserved family B GPCR sequence motif of GWGxP. Although the TM4 helices of the two receptors do not superimpose perfectly (Figure <xref ref-type="fig" rid="F9">9</xref>), this GWGxP motif plays an important structural role in stabilizing the configuration of TM2, TM3, and TM4 (Hollenstein et al., <xref ref-type="bibr" rid="B69">2014</xref>). In CRF1R, TM4 bends at Gly235<sup>4.49b∕4.49</sup> and points Trp236<sup>4.50b∕4.50</sup> toward TM2 and TM3 within the conserved motif. Hydrogen bonds are formed between Trp236<sup>4.50b∕4.50</sup> and Asn157<sup>2.52b∕2.45</sup> on TM2 and Tyr197<sup>3.38b∕3.34</sup> on TM3 (Figure <xref ref-type="fig" rid="F10">10C</xref>). In GCGR, while residues Gly271<sup>4.49b∕4.49</sup> and Trp272<sup>4.50b∕4.50</sup> on TM4, Asn179<sup>2.52b∕2.45</sup> on TM2 and Tyr233<sup>3.38b∕3.34</sup> on TM3 are conserved, hydrogen bonds are formed differently between Trp272<sup>4.50b∕4.50</sup> and Tyr233<sup>3.38b∕3.34</sup> (Figure <xref ref-type="fig" rid="F10">10C</xref>). The inconsistency may result from the ambiguous electron density in the TM4 region of GCGR. Nonetheless, given the high resolution across this region in CRF1R, the observed interactions associated with the GWGxP motif in CRF1R may exist in all family B GPCRs (Hollenstein et al., <xref ref-type="bibr" rid="B70">2013</xref>, <xref ref-type="bibr" rid="B69">2014</xref>).</p>
<p>Moving from the extracellular side to the cytoplasmic side of the transmembrane domains, His<sup>2.50b∕2.43</sup> on TM2 and Glu<sup>3.50b∕3.46</sup> on TM3 are in close proximity in both structures, and their interaction is proposed to be functionally and structurally important (Schipani et al., <xref ref-type="bibr" rid="B136">1995</xref>, <xref ref-type="bibr" rid="B135">1997</xref>; Heller et al., <xref ref-type="bibr" rid="B64">1996</xref>; Hjorth et al., <xref ref-type="bibr" rid="B65">1998</xref>; Vohra et al., <xref ref-type="bibr" rid="B161">2013</xref>; Wootten et al., <xref ref-type="bibr" rid="B165">2013</xref>). Toward the end of TM7, Tyr400<sup>7.57b</sup> of GCGR forms hydrogen bonds with residues Glu245<sup>3.50b</sup> on TM3 and Thr351<sup>6.42b</sup> on TM6 and is positioned in a similar conformation to family A GPCRs that is associated with activation (Rasmussen et al., <xref ref-type="bibr" rid="B127">2011</xref>). Interactions at the equivalent Tyr363<sup>7.57b</sup> of CRF1R were not clearly present in the crystal structure, possibly because helix 8 was removed in the construct, which may have affected the orientation and length of TM7. In fact, this tyrosine residue is conserved among family B GPCRs (Figure <xref ref-type="fig" rid="F8">8</xref>), and is predicted to be associated with the activation and interaction with the G protein (Vohra et al., <xref ref-type="bibr" rid="B161">2013</xref>; Wootten et al., <xref ref-type="bibr" rid="B165">2013</xref>), as discussed later in Section Activation and Allosteric Transition.</p>
<p>Two additional structural features that may be functionally important in the GCGR structure include the additional N-terminal helical turns of TM1 extending far into the extracellular space and an unusually long helix 8 connected to TM7 (Figure <xref ref-type="fig" rid="F9">9</xref>). Even though these structural features may result from artifacts during crystallization, the extension of TM1 may be important in restricting the position of the N-terminal domain for ligand binding. In addition, the unusually long helix 8 connecting to TM7 bends slightly toward the cytoplasm and has its N-terminal involved in interactions with TM 3 and TM6 (Figure <xref ref-type="fig" rid="F10">10F</xref>), which may have functional significance.</p>
</sec>
<sec>
<title>Ligand recognition by the transmembrane domain and druggability of family B GPCRs</title>
<p>Although there is no clear universal cognate peptide ligand-binding site within TMD of family B GPCRs, its location is suggested to be associated with the TMD (Coopman et al., <xref ref-type="bibr" rid="B26">2011</xref>; Miller et al., <xref ref-type="bibr" rid="B99">2011</xref>). The crystal structures of CRF1R and GCGR reveal ligand binding interactions surprisingly deep into the TMDs with wide binding pockets resulting from the large distances between extracellular side of TM2 and TM7, and between that of TM3 and TM7. The deep and wide binding pockets were not observed in any family A GPCRs.</p>
<p>The highly conserved N-terminal motif of family B peptide ligands, which precedes the N-capping motif essential in receptor activation, has been proposed to reach through the juxtamembrane domain deep into the TMD. Upon interaction, the helical segment of the extra long TM1 in the juxtamembrane region is suggested to take a flexible helical structure and thereby position the N-terminal domain relative to the TMD in favor of ligand binding. Moreover, the N-capping of the peptide is suggested to stabilize the receptor-peptide complex (Neumann et al., <xref ref-type="bibr" rid="B103">2008</xref>; Parthier et al., <xref ref-type="bibr" rid="B114">2009</xref>), which is the second step of the two-domain binding model, as discussed above in Section Extracellular Domain: Ligand Binding. Early mutagenesis and photoaffinity studies on family B GPCRs including PTH1R, GLP-1R, and SCTR as well as recent structural studies of CRF1R and GCGR all provide evidence supporting the deep insertion (Figures <xref ref-type="fig" rid="F11">11A,C</xref>; Supplementary Table <xref ref-type="supplementary-material" rid="SM1">S1</xref>; Liaw et al., <xref ref-type="bibr" rid="B89">1997</xref>; Mathi et al., <xref ref-type="bibr" rid="B97">1997</xref>; Tseng and Lin, <xref ref-type="bibr" rid="B156">1997</xref>; Di Paolo et al., <xref ref-type="bibr" rid="B34">1998</xref>, <xref ref-type="bibr" rid="B35">1999</xref>; Hjorth et al., <xref ref-type="bibr" rid="B65">1998</xref>; Cascieri et al., <xref ref-type="bibr" rid="B17">1999</xref>; Xiao et al., <xref ref-type="bibr" rid="B168">2000</xref>; Gardella and Jüppner, <xref ref-type="bibr" rid="B55">2001</xref>; Solano et al., <xref ref-type="bibr" rid="B145">2001</xref>; Perret et al., <xref ref-type="bibr" rid="B115">2002</xref>; Unson et al., <xref ref-type="bibr" rid="B158">2002</xref>; Gensure et al., <xref ref-type="bibr" rid="B56">2003</xref>; Runge et al., <xref ref-type="bibr" rid="B132">2003</xref>; Dong et al., <xref ref-type="bibr" rid="B39">2004</xref>, <xref ref-type="bibr" rid="B41">2012</xref>; Grace et al., <xref ref-type="bibr" rid="B59">2004</xref>; Hoare et al., <xref ref-type="bibr" rid="B67">2006</xref>; Assil-Kishawi et al., <xref ref-type="bibr" rid="B6">2008</xref>; Ceraudo et al., <xref ref-type="bibr" rid="B19">2008</xref>, <xref ref-type="bibr" rid="B18">2012</xref>; Prévost et al., <xref ref-type="bibr" rid="B122">2010</xref>; Underwood et al., <xref ref-type="bibr" rid="B157">2010</xref>; Yaqub et al., <xref ref-type="bibr" rid="B172">2010</xref>; Coopman et al., <xref ref-type="bibr" rid="B26">2011</xref>; Miller et al., <xref ref-type="bibr" rid="B99">2011</xref>; Roberts et al., <xref ref-type="bibr" rid="B130">2011</xref>; Donnelly, <xref ref-type="bibr" rid="B43">2012</xref>; Koole et al., <xref ref-type="bibr" rid="B82">2012</xref>; Koth et al., <xref ref-type="bibr" rid="B83">2012</xref>; Wootten et al., <xref ref-type="bibr" rid="B165">2013</xref>). For instance, Wright and Rodbell showed that the first six residues of the glucagon peptide interact with TMD of GCGR (Wright and Rodbell, <xref ref-type="bibr" rid="B166">1979</xref>). Moreover, mutagenesis studies of GCGR also showed that mutations deep in the TMD directly affect glucagon binding, which involved residues Tyr149<sup>1.4b</sup>, K187<sup>2.60b</sup>, Val191<sup>2.64b</sup>, Gln232<sup>3.37b</sup>, Glu362<sup>6.53b</sup>, and Leu386<sup>7.43b</sup> (Figure <xref ref-type="fig" rid="F11">11</xref>; Cascieri et al., <xref ref-type="bibr" rid="B17">1999</xref>; Perret et al., <xref ref-type="bibr" rid="B115">2002</xref>; Unson et al., <xref ref-type="bibr" rid="B158">2002</xref>; Runge et al., <xref ref-type="bibr" rid="B132">2003</xref>; Prévost et al., <xref ref-type="bibr" rid="B122">2010</xref>; Roberts et al., <xref ref-type="bibr" rid="B130">2011</xref>; Siu et al., <xref ref-type="bibr" rid="B143">2013</xref>). A full receptor-ligand model of the glucagon bound GCGR generated by a combination of structural information of N-terminal domain-ligand complexes and the recent GCGR transmembrane crystal structure also showed a similar binding mode (Hollenstein et al., <xref ref-type="bibr" rid="B69">2014</xref>). Moreover, the results of a series of mutagenesis studies summarized in Figure <xref ref-type="fig" rid="F11">11B</xref> provide additional support for the deep binding site in the TMDs, showing that homologous residues in family B peptide ligands interact with regions deep into the TMDs.</p>
<fig id="F11" position="float">
<label>Figure 11</label>
<caption>
<p><bold>Ligand binding sites of family B GPCRs</bold>. <bold>(A)</bold> Peptide binding pocket of GCGR deep into the TMD. The surface of peptide-binding residues is color-coded regarding the depth (from purple-shallow to magenta-deep). <bold>(B)</bold> Mutation studies on effects of peptide binding in GCGR, CRF1R, GIP, GLP-1R, PTH1R, SCTR, and VPAC<sub>1</sub>R are mapped on a structure-based sequence alignment. Colored residues show 4–10-fold (pink), and &gt;10-fold (red) effects on K<sub>i</sub>/IC<sub>50</sub> values for peptide or ligand potency/EC<sub>50</sub> value. The most conserved residues in TM1–7 of family B GPCRs (X.50<sup>b</sup>, Figure <xref ref-type="fig" rid="F10">10</xref> Box 1) are bolded in orange. Receptor residues that covalently bind peptide ligands in photo-crosslinking or cysteine-trapping studies are boxed blue. Note that TM regions are not displayed in full length. No mutagenesis data for residues of TM4 was found and Supplementary Table <xref ref-type="supplementary-material" rid="SM1">S1</xref> contains experimental details. <bold>(C)</bold> The location of CP-376395 in the CRF<sub>1</sub>R structure is compared to that of selected family A receptor ligands.</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0011"></graphic>
</fig>
<p>The relatively large N-terminal regions of family B peptide ligands may be useful in explaining the wider binding pocket. In fact, the N-terminus of the CRF peptide that binds CRF1R is significantly longer than the N-terminus of the glucagon peptide that binds GCGR (Parthier et al., <xref ref-type="bibr" rid="B114">2009</xref>; Hollenstein et al., <xref ref-type="bibr" rid="B69">2014</xref>). This may explain the wider pocket in CRF1R around the extracellular end of TM6, TM7, and extracellular loop 3, suggesting that the receptors can accommodate large peptide ligands by positioning the TM helices to form a larger binding pocket (Hollenstein et al., <xref ref-type="bibr" rid="B70">2013</xref>).</p>
<p>The deep and wide binding pockets revealed by the two structures also provide new insights into designing molecules to modulate family B GPCRs. It is worth noting that the crystal structure of CRF1R in complex with CP-376395 uncovered an unusual, small-molecule binding pocket that is deep in the intracellular half of the receptor TMD, over 15 Å away from the any ligand-binding site in the known family A GPCR structures (Figures <xref ref-type="fig" rid="F11">11A,C</xref>; Okada et al., <xref ref-type="bibr" rid="B106">2004</xref>; Cherezov et al., <xref ref-type="bibr" rid="B21">2007</xref>; Chien et al., <xref ref-type="bibr" rid="B22">2010</xref>; Wu et al., <xref ref-type="bibr" rid="B167">2010</xref>; Shimamura et al., <xref ref-type="bibr" rid="B140">2011</xref>; Hollenstein et al., <xref ref-type="bibr" rid="B70">2013</xref>). The CP-376395 binding site is defined by TM3, TM5, and TM6 and features both hydrophobic and hydrophilic environments that are compatible with drug-like small organic molecules. It is proposed that CP-376395 acts as an antagonist by stabilizing the inactive conformation of CRF1R, preventing TM6 from moving away from the center of the TM bundle toward the membrane, a widely accepted activation mechanism for family A GPCRs for G protein docking (Bortolato et al., <xref ref-type="bibr" rid="B15">2014</xref>). The residues in direct contact with CP-376395 in fact show high sequence identity among family B GPCR (Figures <xref ref-type="fig" rid="F11">11B,C</xref>), thus this region can potentially be exploited to design small-molecule drugs (Cascieri et al., <xref ref-type="bibr" rid="B17">1999</xref>).</p>
</sec>
<sec>
<title>Activation and allosteric transition</title>
<p>The activation mechanism and transmembrane movements of family A GPCRs have been extensively studied; however, very little has been explored in family B GPCRs. As elaborated by structural and biophysical studies of rhodopsin and other family A GPCRs (Tehan et al., <xref ref-type="bibr" rid="B153">2014</xref>), the most profound allosteric transitions include a large outward movement of TM6 (Ballesteros et al., <xref ref-type="bibr" rid="B8">2001</xref>) and the disruption of the ionic lock between the E/DRY motif on TM3 and acidic residues on TM6 upon activation (Palczewski et al., <xref ref-type="bibr" rid="B110">2000</xref>; Shapiro et al., <xref ref-type="bibr" rid="B138">2002</xref>; Kobilka and Deupi, <xref ref-type="bibr" rid="B81">2007</xref>; Yao et al., <xref ref-type="bibr" rid="B171">2009</xref>). In addition, TM7 bends inward and repositions the tyrosine residue in the conserved NPxxY motif, which connects to helix 8 to prevent the reverse movement of TM7 (Prioleau et al., <xref ref-type="bibr" rid="B123">2002</xref>; Fritze et al., <xref ref-type="bibr" rid="B50">2003</xref>). The bending stabilizes the receptor in an open state. In this state, TM5 repacks against TM6, opening the interaction surface for the G protein. These helical movements and switches provide additional platforms to interact with G proteins. The outward movement of TM6 creates an interacting pocket for the C-terminus of G<sub>α</sub>. Additional interaction sites of G<sub>α</sub> lie in TM3, TM5, and intracellular loop 2 (ICL2) of the receptor (Janz and Farrens, <xref ref-type="bibr" rid="B77">2004</xref>; Kobilka and Deupi, <xref ref-type="bibr" rid="B81">2007</xref>; Choe et al., <xref ref-type="bibr" rid="B23">2011</xref>). Nonetheless, these proposed helical movements found in family A GPCRs have remained almost unexamined in family B GPCRs.</p>
<p>Instead of structural and biophysical characterizations, most studies of transmembrane conformational changes in family B GPCRs have focused on mutagenesis to identify key residues and motifs involved in activation (Figure <xref ref-type="fig" rid="F11">11B</xref>). The structures of CRF1R and GCGR further confirmed the mutagenesis studies with a few highly conserved transmembrane motifs that are potentially important in the activation of family B GPCRs. First, while GCGR and CRF1R do not have the hallmark ionic lock between TM3 and TM6 in family A GPCRs, the H-bonding interaction observed between His<sup>2.50b∕2.43</sup> on TM2 and Glu<sup>3.50b∕3.46</sup> on TM3 may play an equivalent role, breaking upon activation, which allows outward movements of the helix bundle (Hollenstein et al., <xref ref-type="bibr" rid="B70">2013</xref>, <xref ref-type="bibr" rid="B69">2014</xref>; Siu et al., <xref ref-type="bibr" rid="B143">2013</xref>). Second, the conserved NPxxY motif connecting TM7 to the cytoplasmic helix 8 of family A GPCRs is also missing in family B GPCRs. However, the tyrosine of that motif is still highly conserved across family B GPCRs (Figure <xref ref-type="fig" rid="F8">8</xref>). In fact, in GCGR, Tyr400<sup>7.57b</sup> forms hydrogen bonds with residues on TM3 and TM6 and is positioned in a conformation similar to the conformation in family A GPCRs that is associated with activation. In CRF1R, alanine mutations at the equivalent position of Tyr363<sup>7.57b</sup> shift the conformation of the receptor toward an inactive state. This indicates the importance of the conserved tyrosine residue in TM7 in family B GPCR activation, potentially stabilizing the receptor in an open and active conformation. These speculated functions of the conserved residues and motifs in family B GPCRs require careful experimental validation.</p>
</sec>
</sec>
<sec id="s4">
<title>Cytoplasmic domain: G protein coupling</title>
<p>Conformational changes in the TMD, as discussed above, transduce signals from extracellular domains to intracellular domains, selectively activating various isoforms of G proteins that trigger specific downstream physiological responses (bottom, Figure <xref ref-type="fig" rid="F12">12</xref>; Ritter and Hall, <xref ref-type="bibr" rid="B129">2009</xref>). In this section, we will review the general model for interaction of GPCRs and G proteins, emphasizing structural features important for the interaction in family B GPCRs. We will also discuss the proposed structural changes within the cytoplasmic regions upon activation of G proteins.</p>
<fig id="F12" position="float">
<label>Figure 12</label>
<caption>
<p><bold>Interactions of various isoforms of G proteins with the intracellular loops of six family B GPCRs and the downstream signaling pathways activated by the isoforms</bold>. Red indicates G<sub>s</sub>, green G<sub>q</sub>, gray G<sub>i</sub>, yellow G<sub>o</sub>, and blue G<sub>11</sub>. Checkered boxes show two G proteins interact with the same loop. The red box on GLP-1R ICL3 (top left) shows the N-terminal half of the loop associates with G<sub>s</sub> and the C-terminal part of the ICL3 associates with G<sub>i</sub>.</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0012"></graphic>
</fig>
<sec>
<title>General GPCR/G protein interaction model</title>
<p>Two models have been proposed for GPCR coupling to G proteins (Moreira, <xref ref-type="bibr" rid="B101">2014</xref>). These models differ in how and when GPCRs interact with G proteins. The first one is the collision model, where GPCRs and G proteins diffuse freely within the cell membrane and interact via collision (Gilman, <xref ref-type="bibr" rid="B57">1987</xref>). This model, however, is not sufficient to explain the rapid response of many GPCR-mediated pathways, where activation occurs within milliseconds (Vilardaga et al., <xref ref-type="bibr" rid="B159">2003</xref>). The second model involves pre-assembled GPCR/G protein complexes that are formed before ligand binding to receptors. This model has been increasingly accepted and supported by a few experimental studies (Galés et al., <xref ref-type="bibr" rid="B51">2005</xref>, <xref ref-type="bibr" rid="B52">2006</xref>; Qin et al., <xref ref-type="bibr" rid="B125">2011</xref>).</p>
<p>While the collision and pre-assembled models are mostly examined using family A GPCRs (Jastrzebska et al., <xref ref-type="bibr" rid="B78">2010</xref>), they carry particular significance in understanding signaling processes of family B GPCRs. On one hand, previous studies show that the pre-coupling of different G proteins could switch the ligand selectivity in family B GPCRs and thereby modulates the receptor's functions (Ayoub and Pin, <xref ref-type="bibr" rid="B7">2013</xref>). On the other hand, recent evidence suggests that binding of different native ligands with a single GPCR can selectively activate different G proteins. It is currently unknown if the ligand binding influences the selectivity of coupling to various G proteins in the collision model, or if the G protein coupling allows the receptor to change the binding affinity to different ligands in the pre-assembled model. Thus, examining these two models in family B GPCRs is important to unravel the intricacy of the signaling processes of family B GPCRs.</p>
<p>To explore the selectivity in ligands and G proteins for family B GPCRs, PTH1R has been commonly used as a model system (Ferrandon et al., <xref ref-type="bibr" rid="B48">2009</xref>). PTH1R contains two native ligands, PTH and PTHrP. These two ligands share a high degree of structural and sequential similarities. However, recent FRET studies demonstrated the two ligands interact with PTH1R in distinct ways (Ferrandon et al., <xref ref-type="bibr" rid="B48">2009</xref>). While both ligands bind with similar affinity to PTH1R when the receptor is pre-assembled with G<sub>s</sub>, PTHrP has a lower affinity when the receptor is not bound to G<sub>s</sub> (Hoare et al., <xref ref-type="bibr" rid="B68">2001</xref>; Dean et al., <xref ref-type="bibr" rid="B31">2008</xref>; Okazaki et al., <xref ref-type="bibr" rid="B107">2008</xref>). Whether this ligand biased signaling is characteristic of all family B GPCRs requires future studies.</p>
<p>In addition, whether GPCRs function as monomers or oligomers is important in G protein coupling, but still controversial. On one hand, GPCRs, except for the family C members, are proposed to be monomeric and couple to one G protein after receptor activation (as reviewed in Gurevich and Gurevich, <xref ref-type="bibr" rid="B61">2008</xref>). On the other hand, recent evidence supports the idea that GPCRs may function in dimers or higher-order oligomers (Roed et al., <xref ref-type="bibr" rid="B131">2012</xref>). The oligomeric state of the receptor might affect the receptor's ability to couple to and activate different G proteins, which would lead to activation of different downstream signaling pathways (Gao et al., <xref ref-type="bibr" rid="B53">2009</xref>; Harikumar et al., <xref ref-type="bibr" rid="B63">2012</xref>). Although a few studies have used co-immunoprecipitation, BRET, and FRET to understand GPCR oligomerization (Roed et al., <xref ref-type="bibr" rid="B131">2012</xref>), the effect of the implicated oligomerization of family B GPCRs on G protein coupling requires further examination.</p>
<p>A detailed structural characterization of the GPCR/G-protein complex would, of course, provide accurate information about the interactions between the receptor and G protein. However, such structures are only available for two family A GPCRs, rhodopsin and β2 adrenergic receptor (β2AR) (Scheerer et al., <xref ref-type="bibr" rid="B134">2008</xref>; Choe et al., <xref ref-type="bibr" rid="B23">2011</xref>; Rasmussen et al., <xref ref-type="bibr" rid="B127">2011</xref>; Standfuss et al., <xref ref-type="bibr" rid="B146">2011</xref>; Deupi et al., <xref ref-type="bibr" rid="B33">2012</xref>; Singhal et al., <xref ref-type="bibr" rid="B142">2013</xref>). These structures have revealed the importance of ICL2 and ICL3 for GPCR interactions with the Gα subunit of the heterotrimeric G proteins (Rasmussen et al., <xref ref-type="bibr" rid="B127">2011</xref>; Ma et al., <xref ref-type="bibr" rid="B91">2014</xref>; Moreira, <xref ref-type="bibr" rid="B101">2014</xref>). Although family B GPCRs share little sequence similarity with family A GPCRs in the three cytoplasmic loops, mutagenesis studies showed the important role of ICL3 in the selectivity and efficiency of G-protein coupling and activation (Cypess et al., <xref ref-type="bibr" rid="B30">1999</xref>; Hallbrink et al., <xref ref-type="bibr" rid="B62">2001</xref>; Bavec et al., <xref ref-type="bibr" rid="B13">2003</xref>; Conner et al., <xref ref-type="bibr" rid="B25">2006</xref>), as detailed below.</p>
</sec>
<sec>
<title>Interactions and structural changes</title>
<p>Although intracellular loops have been suggested essential for G protein coupling for family B GPCRs, the specific interactions that govern the coupling between GPCRs and G proteins vary from receptor to receptor. Most family B GPCRs can recognize multiple G proteins, such as G<sub>s</sub>, G<sub>q∕11</sub>, and G<sub>i∕o</sub>, increasing the complexity of the signaling processes (Rashid et al., <xref ref-type="bibr" rid="B126">2004</xref>). Here, we will discuss the key interactions involved in G protein recognition for the most heavily investigated family B GPCR, GLP-1R, followed by a summary of the studies for other members in family B.</p>
<p>Studies of GLP-1R reveal that the coupling of various G proteins mainly takes place in ICL3 while ICL1 plays a supplementary role (Figure <xref ref-type="fig" rid="F12">12</xref>, top). A deletion in ICL3 reveals that a key block, Lys334-Leu335-Lys336, in the N-terminal region of this loop is required for coupling to G<sub>s</sub> (Figure <xref ref-type="fig" rid="F12">12</xref>, top left; Takhar et al., <xref ref-type="bibr" rid="B149">1996</xref>). Moreover, Hallbrink et al. used peptides to mimic different parts of ICL3 in GLP-1R and concluded that the N-terminal part of this loop exclusively stimulates G<sub>s</sub> and the C-terminal part exclusively stimulates G<sub>i</sub> (Figure <xref ref-type="fig" rid="F12">12</xref>, top; Hallbrink et al., <xref ref-type="bibr" rid="B62">2001</xref>). Further studies found mutating three other amino acids, Val327, Ile328, and Val331, significantly decrease G<sub>s</sub> activation, further corroborating the data showing that the N-terminal region of ICL3 is involved in G<sub>s</sub> activation (Mathi et al., <xref ref-type="bibr" rid="B97">1997</xref>). In addition to ICL3, ICL1 has also been shown to participate in G<sub>s</sub> coupling, as a single-point mutation in this region (R176A) is sufficient to significantly reduce cAMP production (Figure <xref ref-type="fig" rid="F12">12</xref>, top left; Mathi et al., <xref ref-type="bibr" rid="B97">1997</xref>). ICL1 may also play an essential role in G<sub>i</sub> and G<sub>o</sub> coupling. Studies using a chimeric rhodopsin receptor with ICL1 of GLP-1R in the place of rhodopsin's ICL3 show the receptor signals through G<sub>i</sub> and G<sub>o</sub> by coupling with the GLP-1R ICL1 rather than G<sub>t</sub>, the transducin G protein specifically coupled to rhodopsin (Yamashita et al., <xref ref-type="bibr" rid="B169">2008</xref>). Bavec and coworkers performed a study to explore how peptides derived from the first, second and third intracellular loops of GLP-1R differentiate the G protein signaling pathways. The results suggest that ICL3 is the major determinant for binding to all G proteins (G<sub>s</sub>, G<sub>o</sub>, G<sub>i</sub>, and G<sub>11</sub>), whereas the other two intracellular loops are important in the selectivity of G proteins via modulating the interactions between ICL3 and G proteins (Figure <xref ref-type="fig" rid="F12">12</xref>, top; Bavec et al., <xref ref-type="bibr" rid="B13">2003</xref>).</p>
<p>Studies of other family B GPCRs, including PTH1R, SCTR, and CGRP receptor, reach similar conclusions that ICL3 is the key to G protein coupling while ICL1 and ICL2 may also play subsidiary roles (Figure <xref ref-type="fig" rid="F12">12</xref>). For PTH1R, the N-terminal region of ICL3 has been suggested to interact with G<sub>s</sub> and G<sub>q</sub> (Figure <xref ref-type="fig" rid="F12">12</xref>, middle left; Huang et al., <xref ref-type="bibr" rid="B71">1996</xref>) and the C-terminal region of ICL2, especially the EKKY segment, has been proven important for G<sub>q</sub> coupling (Iidaklein et al., <xref ref-type="bibr" rid="B74">1997</xref>). For SCTR, mutation studies confirm that at least one residue in ICL1 is involved in G<sub>q</sub> signaling, and that the N-terminal and C-terminal regions of ICL3 account for G<sub>s</sub> and G<sub>q</sub> coupling, respectively (Garcia et al., <xref ref-type="bibr" rid="B54">2012</xref>). For CGRP receptor, mutagenesis studies show that ICL1 is important for G<sub>s</sub> coupling and that the N-terminal region of ICL3 is a key G<sub>s</sub> binding motif, while the C-terminal region of ICL3 impairs G<sub>s</sub> binding (Figure <xref ref-type="fig" rid="F12">12</xref>, bottom left; Conner et al., <xref ref-type="bibr" rid="B25">2006</xref>). For VPAC<sub>1</sub>R, ICL2 has no observable effect on G<sub>s</sub> coupling, but Lys322 on ICL3 together with another charged residue (Glu394) on the proximal C-terminal tail of the receptor, play key roles in coupling with G<sub>s</sub> (Figure <xref ref-type="fig" rid="F12">12</xref>, bottom middle; Langer et al., <xref ref-type="bibr" rid="B87">2002</xref>). For GCGR, replacement of all or selected intracellular loops with the ICL1 on D4 dopamine receptor, a family A GPCR, suggests that ICL2 and ICL3 are required for G<sub>s</sub> and G<sub>q</sub> coupling (Figure <xref ref-type="fig" rid="F12">12</xref>, middle right; Cypess et al., <xref ref-type="bibr" rid="B30">1999</xref>).</p>
<p>As summarized in Figure <xref ref-type="fig" rid="F12">12</xref>, the general conclusion is that ICL3 is the key determinant for family B GPCRs to activate G proteins of all types, including G<sub>s</sub>, G<sub>q</sub>, G<sub>i∕o</sub>, and G<sub>11</sub>. The specific regions within each receptor that are responsible for selecting G proteins remain unclear, although accumulating evidence suggests that the N-terminal portion within ICL3 is essential for G<sub>s</sub> coupling and in some receptors for G<sub>q</sub> coupling as well. However, the selectivity of G proteins can also depend on the binding of receptors to various ligands and accessory proteins. Thus, the molecular mechanism behind the selectivity and activation of G proteins for family B GPCRs is a profound research topic that requires further exploration.</p>
</sec>
</sec>
<sec id="s5">
<title>Interaction with accessory proteins</title>
<p>Aside from G proteins, GPCRs can also associate with a variety of accessory proteins that play important roles in modulating receptor functions, including cell surface expression of receptors, selectivity of hormone ligands, and selection of G protein signaling pathways (as reviewed in Couvineau and Laburthe, <xref ref-type="bibr" rid="B28">2012</xref>). These accessory proteins are diverse, including but not limited to receptor-activity-modifying proteins (RAMPs), PDZ domain-containing proteins, cytoskeleton proteins, chaperone molecules, and kinases (Couvineau and Laburthe, <xref ref-type="bibr" rid="B28">2012</xref>). In this section, we will review three representative accessory proteins: RAMPs, calmodulin (CaM), and Na/H exchange regulatory factors (NHERFs). We will focus on their role in the signaling process and the specific sequence motifs responsible for receptor interactions.</p>
<p>Among the accessory proteins that interact with family B GPCRs, the RAMP family is the most extensively studied (Parameswaran and Spielman, <xref ref-type="bibr" rid="B112">2006</xref>). They have been shown to dimerize with family B GPCRs, including the calcitonin receptors, PTH1R, and VPAC<sub>1</sub>R (Christopoulos et al., <xref ref-type="bibr" rid="B24">2003</xref>; Archbold et al., <xref ref-type="bibr" rid="B4">2011</xref>). There are three isoforms of RAMPs (RAMP 1, 2, and 3), which all have a single transmembrane domain and an 80-amino acid N-terminal domain folded into three helices (Figures <xref ref-type="fig" rid="F3">3</xref>, <xref ref-type="fig" rid="F13">13</xref>; Parameswaran and Spielman, <xref ref-type="bibr" rid="B112">2006</xref>). The binding interface between RAMPs and family B GPCRs has not been completely identified. The crystal structure of the CGRP receptor, a heterodimer of CRLR and RAMP1, shows the binding interface between N-terminal domains in the extracellular region of RAMP1 and receptor (Figure <xref ref-type="fig" rid="F13">13</xref>; ter Haar et al., <xref ref-type="bibr" rid="B154">2010</xref>), where hydrogen-bonding, hydrophobic, and electrostatic interactions are key interactions. However, no structural information is available for interactions between RAMP and the transmembrane domain or the cytoplasmic domain.</p>
<fig id="F13" position="float">
<label>Figure 13</label>
<caption>
<p><bold>Ligand binding sites in calcitonin receptors likely involve both the receptor N-terminal domain and RAMPs</bold>. The crystal structures for the calcitonin gene related peptide receptor in complex with two small molecule antagonists (blue). The binding pocket for the small molecules is formed by the interface residues in the two components of the heterodimer: calcitonin receptor-like receptor (CRLR, red) and RAMP1 (ter Haar et al., <xref ref-type="bibr" rid="B154">2010</xref>).</p>
</caption>
<graphic xlink:href="fphar-06-00264-g0013"></graphic>
</fig>
<p>The binding of different RAMP isoforms to family B receptors can modulate at least three functions of family B GPCRs. First, the binding of RAMPs regulates receptor trafficking. For example, the calcitonin receptor (CTR) changes its cell surface expression upon binding to RAMPs (McLatchie et al., <xref ref-type="bibr" rid="B98">1998</xref>). Second, the binding of RAMPs can change the G protein coupling profile. For example, RAMP2 association with VPAC<sub>1</sub>R increases G<sub>q</sub> coupling without affecting the G<sub>s</sub> coupling (Christopoulos et al., <xref ref-type="bibr" rid="B24">2003</xref>). Finally, RAMPs can switch selectivity of ligands. For instance, CRLR binds CGRP, amylin peptide 1, and amylin peptide 2 after interacting with RAMP1, 2, and 3, respectively (Parameswaran and Spielman, <xref ref-type="bibr" rid="B112">2006</xref>). The mechanism of how RAMPs can bias the ligand binding is not fully understood; however, several mutagenesis studies of RAMPs suggested that RAMPs are likely to directly participate in ligand-GPCR interaction (Qi and Hay, <xref ref-type="bibr" rid="B124">2010</xref>; Archbold et al., <xref ref-type="bibr" rid="B4">2011</xref>). Nonetheless, it is still unclear at the molecular level how receptor-RAMP interactions, especially in the transmembrane and cytoplasmic regions, can modulate the above functions of family B GPCRs.</p>
<p>Aside from RAMP, another accessary protein, calmodulin, also interacts with a number of family B GPCRs (Mahon and Shimada, <xref ref-type="bibr" rid="B95">2005</xref>). Calmodulin is a cytosolic calcium-sensing protein. It interacts with receptors in a Ca<sup>2+</sup>-dependent manner through a consensus CaM-binding motif in the receptors' C-terminal tails, which is called the basic 1-5-8-14 domain (Mahon and Shimada, <xref ref-type="bibr" rid="B95">2005</xref>). This binding motif is found in PTH1R, VPAC1<sub>1</sub>R, PAC1R, CRF1R, CTR, GLP-1R, GLP-2R, SCTR, and GHRHR (Mahon and Shimada, <xref ref-type="bibr" rid="B95">2005</xref>). Except SCTR and GHRHR, all these receptors have been shown to bind to CaM. While Mahon and Shimada showed that the binding of CaM to PTH1R decreases activation of G<sub>q</sub> (Mahon and Shimada, <xref ref-type="bibr" rid="B95">2005</xref>), the biological functions of CaM still largely remain unknown.</p>
<p>Another important family of accessory proteins is the four members of the NHERFs (Ardura and Friedman, <xref ref-type="bibr" rid="B5">2011</xref>). These proteins are present in the cytoplasm and contain a C-terminal ezrin-radixin-moesin (ERM)-binding domain and two tandem PDZ domains (Ardura and Friedman, <xref ref-type="bibr" rid="B5">2011</xref>). The ERM-binding domain is known to bind ERM proteins, mediating interactions with actin filaments while the PDZ domain is a common protein interaction module composed of 80–90 amino-acids found in signaling proteins that binds to short amino acid motifs of the C-terminal tail of target proteins (Ardura and Friedman, <xref ref-type="bibr" rid="B5">2011</xref>). The role of PDZ domains of NHERFs is more extensively studied. This domain recognizes two sequences, of which class I is important in interactions with family B GPCRs (Ardura and Friedman, <xref ref-type="bibr" rid="B5">2011</xref>). The class I sequence, ETVM, in the C-terminus of PTH1R facilitates interactions of the receptor with NHERFs (1 and 2) (Mahon et al., <xref ref-type="bibr" rid="B93">2002</xref>; Mahon and Segre, <xref ref-type="bibr" rid="B94">2004</xref>). The PTH1R-NHERF interaction not only leads to recruitment of multiple downstream signaling effectors, but also switches the selectivity of G protein from G<sub>s</sub> to G<sub>q</sub> (Mahon et al., <xref ref-type="bibr" rid="B93">2002</xref>; Wang et al., <xref ref-type="bibr" rid="B162">2010</xref>). Sequence analysis of family B GPCRs suggests the presence of class I PDZ binding motifs in several other members, including VPAC<sub>2</sub>R, SCTR, GLP-2R, and CRF1R (Couvineau and Laburthe, <xref ref-type="bibr" rid="B28">2012</xref>). However, whether or not these receptors interact with NHERFs still needs to be examined.</p>
<p>Aside from the above accessory proteins, many other accessory proteins also interact with family B GPCRs, including calpain and the 14-3-3 protein, adding complexity to the signal transduction process of family B GPCRs (Couvineau and Laburthe, <xref ref-type="bibr" rid="B28">2012</xref>). Indeed, identification of accessory proteins and investigation of their functional roles is still at the infant stage. Continuous efforts are necessary to explore the roles of these accessory proteins in the signaling process of family B GPCRs.</p>
</sec>
<sec id="s6">
<title>Challenges and outlook</title>
<p>To summarize, this review discusses the current understanding of the activation mechanism of family B GPCRs focusing on three steps: (1) ligand binding, (2) transmembrane conformational changes, and (3) G protein coupling. It also discusses how some accessory proteins may modulate activation. While the first step of ligand binding is relatively well understood and described by the two-domain ligand-binding model, the molecular mechanism of transmembrane conformational changes, and G protein coupling have remained largely unknown. Added to this is the crosstalk among ligands, G proteins, and accessory proteins with a family B GPCR, which tunes the structure and dynamics of the receptor and thereby changes the affinity toward different ligands and activates different isoforms of G proteins. All these add complexity to the signaling process of family B GPCRs, making mechanistic studies challenging.</p>
<p>A more complete understanding of the activation mechanism of family B GPCRs is an urgent need. As shown by mechanistic studies of family A GPCRs, biophysical characterizations can be useful: X-ray crystallography (Palczewski et al., <xref ref-type="bibr" rid="B110">2000</xref>; Jaakola et al., <xref ref-type="bibr" rid="B76">2008</xref>; Choe et al., <xref ref-type="bibr" rid="B23">2011</xref>; Rasmussen et al., <xref ref-type="bibr" rid="B127">2011</xref>; Warne et al., <xref ref-type="bibr" rid="B163">2011</xref>) and NMR (Ahuja et al., <xref ref-type="bibr" rid="B2">2009</xref>; Smith, <xref ref-type="bibr" rid="B144">2010</xref>) can determine structures of both inactive and active states, electron paramagnetic resonance can map patterns of helix rearrangement during activation (Altenbach et al., <xref ref-type="bibr" rid="B3">2008</xref>), and other spectroscopic methods, such as fluorescence (Dunham and Farrens, <xref ref-type="bibr" rid="B45">1999</xref>; Yao et al., <xref ref-type="bibr" rid="B170">2006</xref>), Raman (Pan et al., <xref ref-type="bibr" rid="B111">2002</xref>) and Fourier-transformed infrared (Fahmy et al., <xref ref-type="bibr" rid="B47">2000</xref>; Mahalingam et al., <xref ref-type="bibr" rid="B92">2008</xref>) can reveal structures and dynamics of receptors.</p>
<p>Nonetheless, these biophysical characterizations require purification of full-length, functional family B GPCRs in a sufficient amount. Many attempts have been made, ranging from purification from natural sources to heterologous expression systems, such as <italic>E. coli</italic>, mammalian cells, insect cells, and cell-free synthesis systems. So far, only three out of the many studies have shown functional, purified receptors can bind to the ligand and activate G proteins (Ohtaki et al., <xref ref-type="bibr" rid="B105">1998</xref>; Shimada et al., <xref ref-type="bibr" rid="B139">2002</xref>; Mitra et al., <xref ref-type="bibr" rid="B100">2013</xref>). In addition, few studies perform biophysical studies on purified receptors to understand the conformational and dynamic changes during activation.</p>
<p>Recently, our laboratory developed a purification method for family B GPCRs, which directly purifies GPCRs into nanodiscs—disc-shaped particles containing a single layer of lipid bilayer that is stabilized by two membrane scaffold proteins (Mitra et al., <xref ref-type="bibr" rid="B100">2013</xref>). This method reduces the contact of a receptor with detergent and eliminates the step of reconstitution of receptor from detergent solubilized environment into lipid bilayers. The receptor then has both the extracellular and cytoplasmic domains exposed to solution, enabling assessment of molecular interactions from both sides (Leitz et al., <xref ref-type="bibr" rid="B88">2006</xref>; Banerjee et al., <xref ref-type="bibr" rid="B10">2008</xref>; El Moustaine et al., <xref ref-type="bibr" rid="B46">2012</xref>; Inagaki et al., <xref ref-type="bibr" rid="B75">2012</xref>). Unlike detergent systems, nanodiscs can stabilize receptors without the presence of extra micelles that results from maintaining a detergent concentration above the critical micelles concentration (CMC). Thus, the use of nanodiscs in stabilization of receptors can reduce backgrounds in biophysical measurements, such as light scattering in optical spectroscopy or detergent signals in NMR experiments. Hence, the nanodisc system can provide flexibility in designing biophysical experiments (Serebryany et al., <xref ref-type="bibr" rid="B137">2012</xref>), highlighting it as an ideal platform for molecular biophysical characterizations.</p>
<p>Aside from structure-function correlation, the dynamics of the molecular mechanism of family B GPCRs remain largely unknown and unexplored. While solution NMR and single-molecule spectroscopy are commonly used to study protein dynamics, they are not commonly applied to GPCRs. The advancement in computational biology and molecular modeling is deepening our understanding of molecular dynamics (Singh et al., <xref ref-type="bibr" rid="B141">2015</xref>). However, this requires building reliable models for full length family B GPCRs, which is challenging. Even though the transmembrane domain structures of two family B receptors became available, determining the relative orientations of the N-terminal domain and the transmembrane domain remains a difficult task, which requires a synergistic experimental and computational approach. A few groups are working toward building computational models of full-length family B GPCRs, specifically for SCTR, GLP-1R, and PTH1R (Thomas et al., <xref ref-type="bibr" rid="B155">2008</xref>; Coopman et al., <xref ref-type="bibr" rid="B26">2011</xref>; Dong et al., <xref ref-type="bibr" rid="B36">2011a</xref>; Kirkpatrick et al., <xref ref-type="bibr" rid="B80">2012</xref>). These models still require experimental studies of full-length receptors for verification and refinement.</p>
<p>In addition, development of drugs targeting family B GPCRs is still challenging in at least two ways: (1) peptide ligand derivatives as drugs suffer from rapid renal clearance and proteolytic degradation; (2) small molecules as drugs are hard to identify due to limited structural information. There are thus considerable efforts drawn to improve the efficacy of peptide-based drugs (Zuckermann and Kodadek, <xref ref-type="bibr" rid="B174">2009</xref>; Denton et al., <xref ref-type="bibr" rid="B32">2013</xref>; Johnson et al., <xref ref-type="bibr" rid="B79">2014</xref>; Liu et al., <xref ref-type="bibr" rid="B90">2015</xref>); and the current advances in structural biology, especially the crystal structure of small-molecule docked CRF1R's transmembrane, will shed light on rational design of small molecules targeting family B GPCRs.</p>
<p>A theme that runs through this review is the complexity of the signaling processes of family B GPCRs, which comes from modulations of family B GPCRs by ligands, G proteins, and accessory proteins. These modulations change the selectivity of the receptors during ligand sensing and G protein coupling, greatly enriching the information content of cellular communication with the environment and the cellular response to the hormone signaling processes. The field of family B GPCRs is beginning to understand that the signaling process is not only through interactions of a receptor with a specific pair of a ligand and a G protein but also global changes in receptor structure and dynamics regulated by simultaneous and/or sequential interactions with ligand, G proteins, and accessory proteins. A complete understanding of the molecular mechanism of GPCR activation will continue to require a collaborative effort, from high-resolution structural determinations and quantitative biophysical characterizations, to cellular studies of signaling processes and computational molecular modeling, in order to reveal the underlying activation mechanism of family B GPCRs at the fundamental level.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>EY is the recipient of the NSF CAREER Award (MCB-0955407). KC is the recipient of the NIH Biophysics Training Grant (T32 GM008283-27).</p>
</ack>
<sec id="s7" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="http://journal.frontiersin.org/article/10.3389/fphar.2015.00264">http://journal.frontiersin.org/article/10.3389/fphar.2015.00264</ext-link></p>
<supplementary-material content-type="local-data" id="SM1">
<media xlink:href="Table1.DOCX">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adelhorst</surname><given-names>K.</given-names></name><name><surname>Hedegaard</surname><given-names>B. B.</given-names></name><name><surname>Knudsen</surname><given-names>L. B.</given-names></name><name><surname>Kirk</surname><given-names>O.</given-names></name></person-group> (<year>1994</year>). <article-title>Structure-activity studies of glucagon-like peptide-1</article-title>. <source/>J. Biol. Chem.
<volume>269</volume>, <fpage>6275</fpage>–<lpage>6278</lpage>. <pub-id pub-id-type="pmid">8119974</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahuja</surname><given-names>S.</given-names></name><name><surname>Hornak</surname><given-names>V.</given-names></name><name><surname>Yan</surname><given-names>E. C. Y.</given-names></name><name><surname>Syrett</surname><given-names>N.</given-names></name><name><surname>Goncalves</surname><given-names>J. A.</given-names></name><name><surname>Hirshfeld</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Helix movement is coupled to displacement of the second extracellular loop in rhodopsin activation</article-title>. <source/>Nat. Struct. Mol. Biol.
<volume>16</volume>, <fpage>168</fpage>–<lpage>175</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.1549</pub-id><pub-id pub-id-type="pmid">19182802</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altenbach</surname><given-names>C.</given-names></name><name><surname>Kusnetzow</surname><given-names>A. K.</given-names></name><name><surname>Ernst</surname><given-names>O. P.</given-names></name><name><surname>Hofmann</surname><given-names>K. P.</given-names></name><name><surname>Hubbell</surname><given-names>W. L.</given-names></name></person-group> (<year>2008</year>). <article-title>High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>105</volume>, <fpage>7439</fpage>–<lpage>7444</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0802515105</pub-id><pub-id pub-id-type="pmid">18490656</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archbold</surname><given-names>J. K.</given-names></name><name><surname>Flanagan</surname><given-names>J. U.</given-names></name><name><surname>Watkins</surname><given-names>H. A.</given-names></name><name><surname>Gingell</surname><given-names>J. J.</given-names></name><name><surname>Hay</surname><given-names>D. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development</article-title>. <source/>Trends Pharmacol. Sci.
<volume>32</volume>, <fpage>591</fpage>–<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2011.05.007</pub-id><pub-id pub-id-type="pmid">21722971</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ardura</surname><given-names>J. A.</given-names></name><name><surname>Friedman</surname><given-names>P. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Regulation of G Protein-Coupled Receptor Function by Na+/H+ Exchange Regulatory Factors</article-title>. <source/>Pharmacol. Rev.
<volume>63</volume>, <fpage>882</fpage>–<lpage>900</lpage>. <pub-id pub-id-type="doi">10.1124/pr.110.004176</pub-id><pub-id pub-id-type="pmid">21873413</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assil-Kishawi</surname><given-names>I.</given-names></name><name><surname>Samra</surname><given-names>T. A.</given-names></name><name><surname>Mierke</surname><given-names>D. F.</given-names></name><name><surname>Abou-Samra</surname><given-names>A. B.</given-names></name></person-group> (<year>2008</year>). <article-title>Residue 17 of sauvagine cross-links to the first transmembrane domain of corticotropin-releasing factor receptor 1 (CRFR1)</article-title>. <source/>J. Biol. Chem.
<volume>283</volume>, <fpage>35644</fpage>–<lpage>35651</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M806351200</pub-id><pub-id pub-id-type="pmid">18955489</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayoub</surname><given-names>M. A.</given-names></name><name><surname>Pin</surname><given-names>J.-P.</given-names></name></person-group> (<year>2013</year>). <article-title>Interaction of protease-activated receptor 2 with G proteins and β-arrestin 1 studied by bioluminescence resonance energy transfer</article-title>. <source/>Front. Endocrinol.
<volume>4</volume>:<issue>196</issue>. <pub-id pub-id-type="doi">10.3389/fendo.2013.00196</pub-id><pub-id pub-id-type="pmid">24391627</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballesteros</surname><given-names>J. A.</given-names></name><name><surname>Jensen</surname><given-names>A. D.</given-names></name><name><surname>Liapakis</surname><given-names>G.</given-names></name><name><surname>Rasmussen</surname><given-names>S. G.</given-names></name><name><surname>Shi</surname><given-names>L.</given-names></name><name><surname>Gether</surname><given-names>U.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6</article-title>. <source/>J. Biol. Chem.
<volume>276</volume>, <fpage>29171</fpage>–<lpage>29177</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M103747200</pub-id><pub-id pub-id-type="pmid">11375997</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Evanson</surname><given-names>J.</given-names></name><name><surname>Harris</surname><given-names>E.</given-names></name><name><surname>Lowe</surname><given-names>S. L.</given-names></name><name><surname>Thomasson</surname><given-names>K. A.</given-names></name><name><surname>Porter</surname><given-names>J. E.</given-names></name></person-group> (<year>2006</year>). <article-title>Identification of specific calcitonin-like receptor residues important for calcitonin gene-related peptide high affinity binding</article-title>. <source/>BMC Pharmacol.
<volume>6</volume>:<fpage>9</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2210-6-9</pub-id><pub-id pub-id-type="pmid">16776831</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>S.</given-names></name><name><surname>Huber</surname><given-names>T.</given-names></name><name><surname>Sakmar</surname><given-names>T. P.</given-names></name></person-group> (<year>2008</year>). <article-title>Rapid incorporation of functional rhodopsin into nanoscale apolipoprotein bound bilayer (NABB) particles</article-title>. <source/>J. Mol. Biol.
<volume>377</volume>, <fpage>1067</fpage>–<lpage>1081</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2008.01.066</pub-id><pub-id pub-id-type="pmid">18313692</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barwell</surname><given-names>J.</given-names></name><name><surname>Conner</surname><given-names>A.</given-names></name><name><surname>Poyner</surname><given-names>D. R.</given-names></name></person-group> (<year>2011</year>). <article-title>Extracellular loops 1 and 3 and their associated transmembrane regions of the calcitonin receptor-like receptor are needed for CGRP receptor function</article-title>. <source/>Biochim. Biophys. Acta Mol. Cell Res.
<volume>1813</volume>, <fpage>1906</fpage>–<lpage>1916</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2011.06.005</pub-id><pub-id pub-id-type="pmid">21703310</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barwell</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>P. S.</given-names></name><name><surname>Donnelly</surname><given-names>D.</given-names></name><name><surname>Poyner</surname><given-names>D. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Mapping interaction sites within the N-terminus of the calcitonin gene-related peptide receptor; the role of residues 23–60 of the calcitonin receptor-like receptor</article-title>. <source/>Peptides
<volume>31</volume>, <fpage>170</fpage>–<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2009.10.021</pub-id><pub-id pub-id-type="pmid">19913063</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bavec</surname><given-names>A.</given-names></name><name><surname>Hallbrink</surname><given-names>M.</given-names></name><name><surname>Langel</surname><given-names>U.</given-names></name><name><surname>Zorko</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Different role of intracellular loops of glucagon-like peptide-1 receptor in G-protein coupling</article-title>. <source/>Regul. Pept.
<volume>111</volume>, <fpage>137</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1016/S0167-0115(02)00282-3</pub-id><pub-id pub-id-type="pmid">12609761</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergwitz</surname><given-names>C.</given-names></name><name><surname>Gardella</surname><given-names>T. J.</given-names></name><name><surname>Flannery</surname><given-names>M. R.</given-names></name><name><surname>Potts</surname><given-names>J. T.</given-names></name><name><surname>Kronenberg</surname><given-names>H. M.</given-names></name><name><surname>Goldring</surname><given-names>S. R.</given-names></name><etal></etal></person-group>. (<year>1996</year>). <article-title>Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin: evidence for a common pattern of ligand-receptor interaction</article-title>. <source/>J. Biol. Chem.
<volume>271</volume>, <fpage>26469</fpage>–<lpage>26472</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.271.43.26469</pub-id><pub-id pub-id-type="pmid">8900113</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bortolato</surname><given-names>A.</given-names></name><name><surname>Doré</surname><given-names>A. S.</given-names></name><name><surname>Hollenstein</surname><given-names>K.</given-names></name><name><surname>Tehan</surname><given-names>B. G.</given-names></name><name><surname>Mason</surname><given-names>J. S.</given-names></name><name><surname>Marshall</surname><given-names>F. H.</given-names></name></person-group> (<year>2014</year>). <article-title>Structure of Class B GPCRs: new horizons for drug discovery</article-title>. <source/>Br. J. Pharmacol.
<volume>171</volume>, <fpage>3132</fpage>–<lpage>3145</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12689</pub-id><pub-id pub-id-type="pmid">24628305</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgault</surname><given-names>S.</given-names></name><name><surname>Vaudry</surname><given-names>D.</given-names></name><name><surname>Ségalas-Milazzo</surname><given-names>I.</given-names></name><name><surname>Guilhaudis</surname><given-names>L.</given-names></name><name><surname>Couvineau</surname><given-names>A.</given-names></name><name><surname>Laburthe</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor</article-title>. <source/>J. Med. Chem.
<volume>52</volume>, <fpage>3308</fpage>–<lpage>3316</lpage>. <pub-id pub-id-type="doi">10.1021/jm900291j</pub-id><pub-id pub-id-type="pmid">19413310</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascieri</surname><given-names>M. A.</given-names></name><name><surname>Koch</surname><given-names>G. E.</given-names></name><name><surname>Ber</surname><given-names>E.</given-names></name><name><surname>Sadowski</surname><given-names>S. J.</given-names></name><name><surname>Louizides</surname><given-names>D.</given-names></name><name><surname>De Laszlo</surname><given-names>S. E.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor</article-title>. <source/>J. Biol. Chem.
<volume>274</volume>, <fpage>8694</fpage>–<lpage>8697</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.13.8694</pub-id><pub-id pub-id-type="pmid">10085108</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceraudo</surname><given-names>E.</given-names></name><name><surname>Hierso</surname><given-names>R.</given-names></name><name><surname>Tan</surname><given-names>Y. V.</given-names></name><name><surname>Murail</surname><given-names>S.</given-names></name><name><surname>Rouyer-Fessard</surname><given-names>C.</given-names></name><name><surname>Nicole</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction</article-title>. <source/>FASEB J.
<volume>26</volume>, <fpage>2060</fpage>–<lpage>2071</lpage>. <pub-id pub-id-type="doi">10.1096/fj.11-196444</pub-id><pub-id pub-id-type="pmid">22291440</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceraudo</surname><given-names>E.</given-names></name><name><surname>Murail</surname><given-names>S.</given-names></name><name><surname>Tan</surname><given-names>Y.-V.</given-names></name><name><surname>Lacapère</surname><given-names>J.-J.</given-names></name><name><surname>Neumann</surname><given-names>J.-M.</given-names></name><name><surname>Couvineau</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>The vasoactive intestinal peptide (VIP) α-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics</article-title>. <source/>Mol. Endocrinol.
<volume>22</volume>, <fpage>147</fpage>–<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1210/me.2007-0361</pub-id><pub-id pub-id-type="pmid">17885205</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Pinon</surname><given-names>D. I.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name><name><surname>Dong</surname><given-names>M.</given-names></name></person-group> (<year>2009</year>). <article-title>Molecular basis of glucagon-like peptide 1 docking to its intact receptor studied with carboxyl-terminal photolabile probes</article-title>. <source/>J. Biol. Chem.
<volume>284</volume>, <fpage>34135</fpage>–<lpage>34144</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.038109</pub-id><pub-id pub-id-type="pmid">19815559</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cherezov</surname><given-names>V.</given-names></name><name><surname>Rosenbaum</surname><given-names>D. M.</given-names></name><name><surname>Hanson</surname><given-names>M. A.</given-names></name><name><surname>Rasmussen</surname><given-names>S. G.</given-names></name><name><surname>Thian</surname><given-names>F. S.</given-names></name><name><surname>Kobilka</surname><given-names>T. S.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor</article-title>. <source/>Science
<volume>318</volume>, <fpage>1258</fpage>–<lpage>1265</lpage>. <pub-id pub-id-type="doi">10.1126/science.1150577</pub-id><pub-id pub-id-type="pmid">17962520</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chien</surname><given-names>E. Y.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Katritch</surname><given-names>V.</given-names></name><name><surname>Han</surname><given-names>G. W.</given-names></name><name><surname>Hanson</surname><given-names>M. A.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist</article-title>. <source/>Science
<volume>330</volume>, <fpage>1091</fpage>–<lpage>1095</lpage>. <pub-id pub-id-type="doi">10.1126/science.1197410</pub-id><pub-id pub-id-type="pmid">21097933</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choe</surname><given-names>H.-W.</given-names></name><name><surname>Kim</surname><given-names>Y. J.</given-names></name><name><surname>Park</surname><given-names>J. H.</given-names></name><name><surname>Morizumi</surname><given-names>T.</given-names></name><name><surname>Pai</surname><given-names>E. F.</given-names></name><name><surname>Krauß</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Crystal structure of metarhodopsin II</article-title>. <source/>Nature
<volume>471</volume>, <fpage>651</fpage>–<lpage>655</lpage>. <pub-id pub-id-type="doi">10.1038/nature09789</pub-id><pub-id pub-id-type="pmid">21389988</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christopoulos</surname><given-names>A.</given-names></name><name><surname>Christopoulos</surname><given-names>G.</given-names></name><name><surname>Morfis</surname><given-names>M.</given-names></name><name><surname>Udawela</surname><given-names>M.</given-names></name><name><surname>Laburthe</surname><given-names>M.</given-names></name><name><surname>Couvineau</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2003</year>). <article-title>Novel receptor partners and function of receptor activity-modifying proteins</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>3293</fpage>–<lpage>3297</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.C200629200</pub-id><pub-id pub-id-type="pmid">12446722</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conner</surname><given-names>A. C.</given-names></name><name><surname>Simms</surname><given-names>J.</given-names></name><name><surname>Conner</surname><given-names>M. T.</given-names></name><name><surname>Wootten</surname><given-names>D. L.</given-names></name><name><surname>Wheatley</surname><given-names>M.</given-names></name><name><surname>Poyner</surname><given-names>D. R.</given-names></name></person-group> (<year>2006</year>). <article-title>Diverse functional motifs within the three intracellular loops of the CGRP(1) receptor</article-title>. <source/>Biochemistry
<volume>45</volume>, <fpage>12976</fpage>–<lpage>12985</lpage>. <pub-id pub-id-type="doi">10.1021/bi0615801</pub-id><pub-id pub-id-type="pmid">17059214</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coopman</surname><given-names>K.</given-names></name><name><surname>Wallis</surname><given-names>R.</given-names></name><name><surname>Robb</surname><given-names>G.</given-names></name><name><surname>Brown</surname><given-names>A. J.</given-names></name><name><surname>Wilkinson</surname><given-names>G. F.</given-names></name><name><surname>Timms</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor</article-title>. <source/>Mol. Endocrinol.
<volume>25</volume>, <fpage>1804</fpage>–<lpage>1818</lpage>. <pub-id pub-id-type="doi">10.1210/me.2011-1160</pub-id><pub-id pub-id-type="pmid">21868452</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couvineau</surname><given-names>A.</given-names></name><name><surname>Gaudin</surname><given-names>P.</given-names></name><name><surname>Maoret</surname><given-names>J. J.</given-names></name><name><surname>Rouyerfessard</surname><given-names>C.</given-names></name><name><surname>Nicole</surname><given-names>P.</given-names></name><name><surname>Laburthe</surname><given-names>M.</given-names></name></person-group> (<year>1995</year>). <article-title>Highly conserved Aspartate 68, Tryptophane 73 and Glycine 109 in the N-terminal extracellular domain of the human VIP receptor are essential for its ability to bind VIP</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>206</volume>, <fpage>246</fpage>–<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1995.1034</pub-id><pub-id pub-id-type="pmid">7818527</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couvineau</surname><given-names>A.</given-names></name><name><surname>Laburthe</surname><given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>The family B1 GPCR: structural aspects and interaction with accessory proteins</article-title>. <source/>Curr. Drug Targets
<volume>13</volume>, <fpage>103</fpage>–<lpage>115</lpage>. <pub-id pub-id-type="doi">10.2174/138945012798868434</pub-id><pub-id pub-id-type="pmid">21777182</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crocker</surname><given-names>E.</given-names></name><name><surname>Eilers</surname><given-names>M.</given-names></name><name><surname>Ahuja</surname><given-names>S.</given-names></name><name><surname>Hornak</surname><given-names>V.</given-names></name><name><surname>Hirshfeld</surname><given-names>A.</given-names></name><name><surname>Sheves</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Location of Trp265 in metarhodopsin II: implications for the activation mechanism of the visual receptor rhodopsin</article-title>. <source/>J. Mol. Biol.
<volume>357</volume>, <fpage>163</fpage>–<lpage>172</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2005.12.046</pub-id><pub-id pub-id-type="pmid">16414074</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cypess</surname><given-names>A. M.</given-names></name><name><surname>Unson</surname><given-names>C. G.</given-names></name><name><surname>Wu</surname><given-names>C. R.</given-names></name><name><surname>Sakmar</surname><given-names>T. P.</given-names></name></person-group> (<year>1999</year>). <article-title>Two cytoplasmic loops of the glucagon receptor are required to elevate cAMP or intracellular calcium</article-title>. <source/>J. Biol. Chem.
<volume>274</volume>, <fpage>19455</fpage>–<lpage>19464</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.27.19455</pub-id><pub-id pub-id-type="pmid">10383462</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>T.</given-names></name><name><surname>Vilardaga</surname><given-names>J. P.</given-names></name><name><surname>Potts</surname><given-names>J. T.</given-names></name><name><surname>Gardella</surname><given-names>T. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Altered selectivity of parathyroid hormone (PTH) and PTH-Related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor</article-title>. <source/>Mol. Endocrinol.
<volume>22</volume>, <fpage>156</fpage>–<lpage>166</lpage>. <pub-id pub-id-type="doi">10.1210/me.2007-0274</pub-id><pub-id pub-id-type="pmid">17872377</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Denton</surname><given-names>E. V.</given-names></name><name><surname>Craig</surname><given-names>C. J.</given-names></name><name><surname>Pongratz</surname><given-names>R. L.</given-names></name><name><surname>Appelbaum</surname><given-names>J. S.</given-names></name><name><surname>Doerner</surname><given-names>A. E.</given-names></name><name><surname>Narayanan</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>A β-peptide agonist of the GLP-1 receptor, a class B GPCR</article-title>. <source/>Org. Lett.
<volume>15</volume>, <fpage>5318</fpage>–<lpage>5321</lpage>. <pub-id pub-id-type="doi">10.1021/ol402568j</pub-id><pub-id pub-id-type="pmid">24087900</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deupi</surname><given-names>X.</given-names></name><name><surname>Edwards</surname><given-names>P.</given-names></name><name><surname>Singhal</surname><given-names>A.</given-names></name><name><surname>Nickle</surname><given-names>B.</given-names></name><name><surname>Oprian</surname><given-names>D.</given-names></name><name><surname>Schertler</surname><given-names>G.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Stabilized G protein binding site in the structure of constitutively active metarhodopsin-II</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>109</volume>, <fpage>119</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1114089108</pub-id><pub-id pub-id-type="pmid">22198838</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Paolo</surname><given-names>E.</given-names></name><name><surname>De Neef</surname><given-names>P.</given-names></name><name><surname>Moguilevsky</surname><given-names>N.</given-names></name><name><surname>Petry</surname><given-names>H.</given-names></name><name><surname>Bollen</surname><given-names>A.</given-names></name><name><surname>Waelbroeck</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>1998</year>). <article-title>Contribution of the second transmembrane helix of the secretin receptor to the positioning of secretin</article-title>. <source/>FEBS Lett.
<volume>424</volume>, <fpage>207</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-5793(98)00175-6</pub-id><pub-id pub-id-type="pmid">9539152</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Paolo</surname><given-names>E.</given-names></name><name><surname>Petry</surname><given-names>H.</given-names></name><name><surname>Moguilevsky</surname><given-names>N.</given-names></name><name><surname>Bollen</surname><given-names>A.</given-names></name><name><surname>De Neef</surname><given-names>P.</given-names></name><name><surname>Waelbroeck</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>1999</year>). <article-title>Mutations of aromatic residues in the first transmembrane helix impair signalling by the secretin receptor</article-title>. <source/>Recept. Channels
<volume>6</volume>, <fpage>309</fpage>–<lpage>315</lpage>. <pub-id pub-id-type="pmid">10412723</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Lam</surname><given-names>P. C.-H.</given-names></name><name><surname>Pinon</surname><given-names>D. I.</given-names></name><name><surname>Hosohata</surname><given-names>K.</given-names></name><name><surname>Orry</surname><given-names>A.</given-names></name><name><surname>Sexton</surname><given-names>P. M.</given-names></name><etal></etal></person-group>. (<year>2011a</year>). <article-title>Molecular basis of secretin docking to its intact receptor using multiple photolabile probes distributed throughout the pharmacophore</article-title>. <source/>J. Biol. Chem.
<volume>286</volume>, <fpage>23888</fpage>–<lpage>23899</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.245969</pub-id><pub-id pub-id-type="pmid">21566140</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Lam</surname><given-names>P. C.-H.</given-names></name><name><surname>Pinon</surname><given-names>D. I.</given-names></name><name><surname>Sexton</surname><given-names>P. M.</given-names></name><name><surname>Abagyan</surname><given-names>R.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Spatial approximation between secretin residue five and the third extracellular loop of its receptor provides new insight into the molecular basis of natural agonist binding</article-title>. <source/>Mol. Pharmacol.
<volume>74</volume>, <fpage>413</fpage>–<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1124/mol.108.047209</pub-id><pub-id pub-id-type="pmid">18467541</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Le</surname><given-names>A.</given-names></name><name><surname>Te</surname><given-names>J. A.</given-names></name><name><surname>Pinon</surname><given-names>D. I.</given-names></name><name><surname>Bordner</surname><given-names>A. J.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name></person-group> (<year>2011b</year>). <article-title>Importance of each residue within secretin for receptor binding and biological activity</article-title>. <source/>Biochemistry
<volume>50</volume>, <fpage>2983</fpage>–<lpage>2993</lpage>. <pub-id pub-id-type="doi">10.1021/bi200133u</pub-id><pub-id pub-id-type="pmid">21388146</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Pinon</surname><given-names>D. I.</given-names></name><name><surname>Cox</surname><given-names>R. F.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name></person-group> (<year>2004</year>). <article-title>Importance of the amino terminus in secretin family g protein-coupled receptors: intrinsic photoaffinity labeling establishes initial docking constraints for the calcitonin receptor</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>1167</fpage>–<lpage>1175</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M305719200</pub-id><pub-id pub-id-type="pmid">14583624</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Pinon</surname><given-names>D. I.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Insights into the impact of phenolic residue incorporation at each position along secretin for receptor binding and biological activity</article-title>. <source/>Regul. Pept.
<volume>180</volume>, <fpage>5</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/j.regpep.2012.10.001</pub-id><pub-id pub-id-type="pmid">23142313</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Xu</surname><given-names>X.</given-names></name><name><surname>Ball</surname><given-names>A. M.</given-names></name><name><surname>Makhoul</surname><given-names>J. A.</given-names></name><name><surname>Lam</surname><given-names>P. C.-H.</given-names></name><name><surname>Pinon</surname><given-names>D. I.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Mapping spatial approximations between the amino terminus of secretin and each of the extracellular loops of its receptor using cysteine trapping</article-title>. <source/>FASEB J.
<volume>26</volume>, <fpage>5092</fpage>–<lpage>5105</lpage>. <pub-id pub-id-type="doi">10.1096/fj.12-212399</pub-id><pub-id pub-id-type="pmid">22964305</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Zang</surname><given-names>M.</given-names></name><name><surname>Pinon</surname><given-names>D. I.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Lybrand</surname><given-names>T. P.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name></person-group> (<year>2002</year>). <article-title>Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus</article-title>. <source/>Mol. Endocrinol.
<volume>16</volume>, <fpage>2490</fpage>–<lpage>2501</lpage>. <pub-id pub-id-type="doi">10.1210/me.2002-0111</pub-id><pub-id pub-id-type="pmid">12403838</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>D.</given-names></name></person-group> (<year>2012</year>). <article-title>The structure and function of the glucagon-like peptide-1 receptor and its ligands</article-title>. <source/>Br. J. Pharmacol.
<volume>166</volume>, <fpage>27</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01687.x</pub-id><pub-id pub-id-type="pmid">21950636</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>K.</given-names></name><name><surname>Nicole</surname><given-names>P.</given-names></name><name><surname>Couvineau</surname><given-names>A.</given-names></name><name><surname>Laburthe</surname><given-names>M.</given-names></name></person-group> (<year>1997</year>). <article-title>Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>230</volume>, <fpage>289</fpage>–<lpage>292</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1996.5949</pub-id><pub-id pub-id-type="pmid">9016768</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunham</surname><given-names>T. D.</given-names></name><name><surname>Farrens</surname><given-names>D. L.</given-names></name></person-group> (<year>1999</year>). <article-title>Conformational changes in rhodopsin - movement of helix F detected by site-specific chemical labeling and fluorescence spectroscopy</article-title>. <source/>J. Biol. Chem.
<volume>274</volume>, <fpage>1683</fpage>–<lpage>1690</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.274.3.1683</pub-id><pub-id pub-id-type="pmid">9880548</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Moustaine</surname><given-names>D.</given-names></name><name><surname>Granier</surname><given-names>S.</given-names></name><name><surname>Doumazane</surname><given-names>E.</given-names></name><name><surname>Scholler</surname><given-names>P.</given-names></name><name><surname>Rahmeh</surname><given-names>R.</given-names></name><name><surname>Bron</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>109</volume>, <fpage>16342</fpage>–<lpage>16347</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1205838109</pub-id><pub-id pub-id-type="pmid">22988116</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahmy</surname><given-names>K.</given-names></name><name><surname>Sakmar</surname><given-names>T. P.</given-names></name><name><surname>Siebert</surname><given-names>F.</given-names></name></person-group> (<year>2000</year>). <article-title>Transducin-dependent protonation of glutamic acid 134 in Rhodopsin†</article-title>. <source/>Biochemistry
<volume>39</volume>, <fpage>10607</fpage>–<lpage>10612</lpage>. <pub-id pub-id-type="doi">10.1021/bi000912d</pub-id><pub-id pub-id-type="pmid">10956053</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrandon</surname><given-names>S.</given-names></name><name><surname>Feinstein</surname><given-names>T. N.</given-names></name><name><surname>Castro</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Bouley</surname><given-names>R.</given-names></name><name><surname>Potts</surname><given-names>J. T.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Sustained cyclic AMP production by parathyroid hormone receptor endocytosis</article-title>. <source/>Nat. Chem. Biol.
<volume>5</volume>, <fpage>734</fpage>–<lpage>742</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.206</pub-id><pub-id pub-id-type="pmid">19701185</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fredriksson</surname><given-names>R.</given-names></name><name><surname>Lagerstrom</surname><given-names>M. C.</given-names></name><name><surname>Lundin</surname><given-names>L. G.</given-names></name><name><surname>Schioth</surname><given-names>H. B.</given-names></name></person-group> (<year>2003</year>). <article-title>The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints</article-title>. <source/>Mol. Pharmacol.
<volume>63</volume>, <fpage>1256</fpage>–<lpage>1272</lpage>. <pub-id pub-id-type="doi">10.1124/mol.63.6.1256</pub-id><pub-id pub-id-type="pmid">12761335</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fritze</surname><given-names>O.</given-names></name><name><surname>Filipek</surname><given-names>S.</given-names></name><name><surname>Kuksa</surname><given-names>V.</given-names></name><name><surname>Palczewski</surname><given-names>K.</given-names></name><name><surname>Hofmann</surname><given-names>K. P.</given-names></name><name><surname>Ernst</surname><given-names>O. P.</given-names></name></person-group> (<year>2003</year>). <article-title>Role of the conserved NPxxY (x) 5, 6F motif in the rhodopsin ground state and during activation</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>100</volume>, <fpage>2290</fpage>–<lpage>2295</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0435715100</pub-id><pub-id pub-id-type="pmid">12601165</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galés</surname><given-names>C.</given-names></name><name><surname>Rebois</surname><given-names>R. V.</given-names></name><name><surname>Hogue</surname><given-names>M.</given-names></name><name><surname>Trieu</surname><given-names>P.</given-names></name><name><surname>Breit</surname><given-names>A.</given-names></name><name><surname>Hébert</surname><given-names>T. E.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Real-time monitoring of receptor and G-protein interactions in living cells</article-title>. <source/>Nat. Methods
<volume>2</volume>, <fpage>177</fpage>–<lpage>184</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth743</pub-id><pub-id pub-id-type="pmid">15782186</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galés</surname><given-names>C.</given-names></name><name><surname>Van Durm</surname><given-names>J. J. J.</given-names></name><name><surname>Schaak</surname><given-names>S.</given-names></name><name><surname>Pontier</surname><given-names>S.</given-names></name><name><surname>Percherancier</surname><given-names>Y.</given-names></name><name><surname>Audet</surname><given-names>M.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes</article-title>. <source/>Nat. Struct. Mol. Biol.
<volume>13</volume>, <fpage>778</fpage>–<lpage>786</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb1134</pub-id><pub-id pub-id-type="pmid">16906158</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Harikumar</surname><given-names>K. G.</given-names></name><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Lam</surname><given-names>P. C.-H.</given-names></name><name><surname>Sexton</surname><given-names>P. M.</given-names></name><name><surname>Christopoulos</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Functional importance of a structurally distinct homodimeric complex of the family BG protein-coupled secretin receptor</article-title>. <source/>Mol. Pharmacol.
<volume>76</volume>, <fpage>264</fpage>–<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1124/mol.109.055756</pub-id><pub-id pub-id-type="pmid">19429716</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>G. L.</given-names></name><name><surname>Dong</surname><given-names>M. Q.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name></person-group> (<year>2012</year>). <article-title>Differential determinants for coupling of distinct G proteins with the class B secretin receptor</article-title>. <source/>Am. J. Physiol. Cell Physiol.
<volume>302</volume>, <fpage>C1202</fpage>–<lpage>C1212</lpage>. <pub-id pub-id-type="doi">10.1152/ajpcell.00273.2011</pub-id><pub-id pub-id-type="pmid">22277758</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardella</surname><given-names>T. J.</given-names></name><name><surname>Jüppner</surname><given-names>H.</given-names></name></person-group> (<year>2001</year>). <article-title>Molecular properties of the PTH/PTHrP receptor</article-title>. <source/>Trends Endocrinol. Metab.
<volume>12</volume>, <fpage>210</fpage>–<lpage>217</lpage>. <pub-id pub-id-type="doi">10.1016/S1043-2760(01)00409-X</pub-id><pub-id pub-id-type="pmid">11397646</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gensure</surname><given-names>R. C.</given-names></name><name><surname>Shimizu</surname><given-names>N.</given-names></name><name><surname>Tsang</surname><given-names>J.</given-names></name><name><surname>Gardella</surname><given-names>T. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Identification of a contact site for residue 19 of parathyroid hormone (PTH) and PTH-related protein analogs in transmembrane domain two of the type 1 PTH receptor</article-title>. <source/>Mol. Endocrinol.
<volume>17</volume>, <fpage>2647</fpage>–<lpage>2658</lpage>. <pub-id pub-id-type="doi">10.1210/me.2003-0275</pub-id><pub-id pub-id-type="pmid">12947048</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilman</surname><given-names>A. G.</given-names></name></person-group> (<year>1987</year>). <article-title>G-proteins - transducers of receptor-generated signals</article-title>. <source/>Annu. Rev. Biochem.
<volume>56</volume>, <fpage>615</fpage>–<lpage>649</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.bi.56.070187.003151</pub-id><pub-id pub-id-type="pmid">3113327</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gkountelias</surname><given-names>K.</given-names></name><name><surname>Tselios</surname><given-names>T.</given-names></name><name><surname>Venihaki</surname><given-names>M.</given-names></name><name><surname>Deraos</surname><given-names>G.</given-names></name><name><surname>Lazaridis</surname><given-names>I.</given-names></name><name><surname>Rassouli</surname><given-names>O.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding</article-title>. <source/>Mol. Pharmacol.
<volume>75</volume>, <fpage>793</fpage>–<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1124/mol.108.052423</pub-id><pub-id pub-id-type="pmid">19124613</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grace</surname><given-names>C. R. R.</given-names></name><name><surname>Perrin</surname><given-names>M. H.</given-names></name><name><surname>Digruccio</surname><given-names>M. R.</given-names></name><name><surname>Miller</surname><given-names>C. L.</given-names></name><name><surname>Rivier</surname><given-names>J. E.</given-names></name><name><surname>Vale</surname><given-names>W. W.</given-names></name><etal></etal></person-group>. (<year>2004</year>). <article-title>NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>101</volume>, <fpage>12836</fpage>–<lpage>12841</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0404702101</pub-id><pub-id pub-id-type="pmid">15326300</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grace</surname><given-names>C. R. R.</given-names></name><name><surname>Perrin</surname><given-names>M. H.</given-names></name><name><surname>Gulyas</surname><given-names>J.</given-names></name><name><surname>Digruccio</surname><given-names>M. R.</given-names></name><name><surname>Cantle</surname><given-names>J. P.</given-names></name><name><surname>Rivier</surname><given-names>J. E.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>104</volume>, <fpage>4858</fpage>–<lpage>4863</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0700682104</pub-id><pub-id pub-id-type="pmid">17360332</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurevich</surname><given-names>V. V.</given-names></name><name><surname>Gurevich</surname><given-names>E. V.</given-names></name></person-group> (<year>2008</year>). <article-title>GPCR monomers and oligomers: it takes all kinds</article-title>. <source/>Trends Neurosci.
<volume>31</volume>, <fpage>74</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2007.11.007</pub-id><pub-id pub-id-type="pmid">18199492</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallbrink</surname><given-names>M.</given-names></name><name><surname>Holmqvist</surname><given-names>T.</given-names></name><name><surname>Olsson</surname><given-names>M.</given-names></name><name><surname>Ostenson</surname><given-names>C. G.</given-names></name><name><surname>Efendic</surname><given-names>S.</given-names></name><name><surname>Langel</surname><given-names>U.</given-names></name></person-group> (<year>2001</year>). <article-title>Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation</article-title>. <source/>Biochim. Biophys. Acta
<volume>1546</volume>, <fpage>79</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1016/S0167-4838(00)00270-3</pub-id><pub-id pub-id-type="pmid">11257510</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harikumar</surname><given-names>K. G.</given-names></name><name><surname>Wootten</surname><given-names>D.</given-names></name><name><surname>Pinon</surname><given-names>D. I.</given-names></name><name><surname>Koole</surname><given-names>C.</given-names></name><name><surname>Ball</surname><given-names>A. M.</given-names></name><name><surname>Furness</surname><given-names>S. G.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Glucagon-like peptide-1 receptor dimerization differentially regulates agonist signaling but does not affect small molecule allostery</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>109</volume>, <fpage>18607</fpage>–<lpage>18612</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1205227109</pub-id><pub-id pub-id-type="pmid">23091034</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heller</surname><given-names>R. S.</given-names></name><name><surname>Kieffer</surname><given-names>T. J.</given-names></name><name><surname>Habener</surname><given-names>J. F.</given-names></name></person-group> (<year>1996</year>). <article-title>Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>223</volume>, <fpage>624</fpage>–<lpage>632</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1996.0945</pub-id><pub-id pub-id-type="pmid">8687446</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hjorth</surname><given-names>S. A.</given-names></name><name><surname>Orskov</surname><given-names>C.</given-names></name><name><surname>Schwartz</surname><given-names>T. W.</given-names></name></person-group> (<year>1998</year>). <article-title>Constitutive activity of glucagon receptor mutants</article-title>. <source/>Mol. Endocrinol.
<volume>12</volume>, <fpage>78</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1210/mend.12.1.0045</pub-id><pub-id pub-id-type="pmid">9440812</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoare</surname><given-names>S. R.</given-names></name></person-group> (<year>2005</year>). <article-title>Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors</article-title>. <source/>Drug Discov. Today
<volume>10</volume>, <fpage>417</fpage>–<lpage>427</lpage>. <pub-id pub-id-type="doi">10.1016/S1359-6446(05)03370-2</pub-id><pub-id pub-id-type="pmid">15808821</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoare</surname><given-names>S. R.</given-names></name><name><surname>Brown</surname><given-names>B. T.</given-names></name><name><surname>Santos</surname><given-names>M. A.</given-names></name><name><surname>Malany</surname><given-names>S.</given-names></name><name><surname>Betz</surname><given-names>S. F.</given-names></name><name><surname>Grigoriadis</surname><given-names>D. E.</given-names></name></person-group> (<year>2006</year>). <article-title>Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor</article-title>. <source/>Biochem. Pharmacol.
<volume>72</volume>, <fpage>244</fpage>–<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2006.04.007</pub-id><pub-id pub-id-type="pmid">16750175</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoare</surname><given-names>S. R. J.</given-names></name><name><surname>Gardella</surname><given-names>T. J.</given-names></name><name><surname>Usdin</surname><given-names>T. B.</given-names></name></person-group> (<year>2001</year>). <article-title>Evaluating the signal transduction mechanism of the parathyroid hormone 1 receptor - effect of receptor-G-protein interaction on the ligand binding mechanism and receptor conformation</article-title>. <source/>J. Biol. Chem.
<volume>276</volume>, <fpage>7741</fpage>–<lpage>7753</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M009395200</pub-id><pub-id pub-id-type="pmid">11108715</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollenstein</surname><given-names>K.</given-names></name><name><surname>De Graaf</surname><given-names>C.</given-names></name><name><surname>Bortolato</surname><given-names>A.</given-names></name><name><surname>Wang</surname><given-names>M.-W.</given-names></name><name><surname>Marshall</surname><given-names>F. H.</given-names></name><name><surname>Stevens</surname><given-names>R. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Insights into the structure of class B GPCRs</article-title>. <source/>Trends Pharmacol. Sci.
<volume>35</volume>, <fpage>12</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2013.11.001</pub-id><pub-id pub-id-type="pmid">24359917</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollenstein</surname><given-names>K.</given-names></name><name><surname>Kean</surname><given-names>J.</given-names></name><name><surname>Bortolato</surname><given-names>A.</given-names></name><name><surname>Cheng</surname><given-names>R. K.</given-names></name><name><surname>Doré</surname><given-names>A. S.</given-names></name><name><surname>Jazayeri</surname><given-names>A.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Structure of class B GPCR corticotropin-releasing factor receptor 1</article-title>. <source/>Nature
<volume>449</volume>, <fpage>438</fpage>–<lpage>443</lpage>. <pub-id pub-id-type="doi">10.1038/nature12357</pub-id><pub-id pub-id-type="pmid">23863939</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Z. M.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Pratt</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>T. H.</given-names></name><name><surname>Bambino</surname><given-names>T.</given-names></name><name><surname>Nissenson</surname><given-names>R. A.</given-names></name><etal></etal></person-group>. (<year>1996</year>). <article-title>The N-terminal region of the third intracellular loop of the parathyroid hormone (PTH)/PTH-related peptide receptor is critical for coupling to cAMP and inositol phosphate/Ca2+ signal transduction pathways</article-title>. <source/>J. Biol. Chem.
<volume>271</volume>, <fpage>33382</fpage>–<lpage>33389</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.271.52.33382</pub-id><pub-id pub-id-type="pmid">8969199</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Igarashi</surname><given-names>H.</given-names></name><name><surname>Ito</surname><given-names>T.</given-names></name><name><surname>Hou</surname><given-names>W.</given-names></name><name><surname>Mantey</surname><given-names>S. A.</given-names></name><name><surname>Pradhan</surname><given-names>T. K.</given-names></name><name><surname>Ulrich</surname><given-names>C. D.</given-names></name><etal></etal></person-group>. (<year>2002a</year>). <article-title>Elucidation of vasoactive intestinal peptide pharmacophore for VPAC1 receptors in human, rat, and guinea pig</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>301</volume>, <fpage>37</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.301.1.37</pub-id><pub-id pub-id-type="pmid">11907155</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Igarashi</surname><given-names>H.</given-names></name><name><surname>Ito</surname><given-names>T.</given-names></name><name><surname>Pradhan</surname><given-names>T. K.</given-names></name><name><surname>Mantey</surname><given-names>S. A.</given-names></name><name><surname>Hou</surname><given-names>W.</given-names></name><name><surname>Coy</surname><given-names>D. H.</given-names></name><etal></etal></person-group>. (<year>2002b</year>). <article-title>Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC2 receptors in human and rat and comparison to the pharmacophore for VPAC1 receptors</article-title>. <source/>J. Pharmacol. Exp. Ther.
<volume>303</volume>, <fpage>445</fpage>–<lpage>460</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0019682</pub-id><pub-id pub-id-type="pmid">12388623</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iidaklein</surname><given-names>A.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Takemura</surname><given-names>M.</given-names></name><name><surname>Drakes</surname><given-names>M. T.</given-names></name><name><surname>Potts</surname><given-names>J. T.</given-names></name><name><surname>Abousamra</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>1997</year>). <article-title>Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTH-stimulated phospholipase C activity</article-title>. <source/>J. Biol. Chem.
<volume>272</volume>, <fpage>6882</fpage>–<lpage>6889</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.272.11.6882</pub-id><pub-id pub-id-type="pmid">9054374</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inagaki</surname><given-names>S.</given-names></name><name><surname>Ghirlando</surname><given-names>R.</given-names></name><name><surname>White</surname><given-names>J. F.</given-names></name><name><surname>Gvozdenovic-Jeremic</surname><given-names>J.</given-names></name><name><surname>Northup</surname><given-names>J. K.</given-names></name><name><surname>Grisshammer</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>Modulation of the interaction between neurotensin receptor NTS1 and Gq protein by lipid</article-title>. <source/>J. Mol. Biol.
<volume>417</volume>, <fpage>95</fpage>–<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2012.01.023</pub-id><pub-id pub-id-type="pmid">22306739</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaakola</surname><given-names>V. P.</given-names></name><name><surname>Griffith</surname><given-names>M. T.</given-names></name><name><surname>Hanson</surname><given-names>M. A.</given-names></name><name><surname>Cherezov</surname><given-names>V.</given-names></name><name><surname>Chien</surname><given-names>E. Y. T.</given-names></name><name><surname>Lane</surname><given-names>J. R.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>The 2.6 angstrom crystal structure of a human A(2A) adenosine receptor bound to an antagonist</article-title>. <source/>Science
<volume>322</volume>, <fpage>1211</fpage>–<lpage>1217</lpage>. <pub-id pub-id-type="doi">10.1126/science.1164772</pub-id><pub-id pub-id-type="pmid">18832607</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janz</surname><given-names>J. M.</given-names></name><name><surname>Farrens</surname><given-names>D. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Rhodopsin activation exposes a key hydrophobic binding site for the transducin α-subunit C terminus</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>29767</fpage>–<lpage>29773</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M402567200</pub-id><pub-id pub-id-type="pmid">15070895</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jastrzebska</surname><given-names>B.</given-names></name><name><surname>Tsybovsky</surname><given-names>Y.</given-names></name><name><surname>Palczewski</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>Complexes between photoactivated rhodopsin and transducin: progress and questions</article-title>. <source/>Biochem. J.
<volume>428</volume>, <fpage>1</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1042/BJ20100270</pub-id><pub-id pub-id-type="pmid">20423327</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>L. M.</given-names></name><name><surname>Barrick</surname><given-names>S.</given-names></name><name><surname>Hager</surname><given-names>M. V.</given-names></name><name><surname>McFedries</surname><given-names>A.</given-names></name><name><surname>Homan</surname><given-names>E. A.</given-names></name><name><surname>Rabaglia</surname><given-names>M. E.</given-names></name><etal></etal></person-group>. (<year>2014</year>). <article-title>A potent α/β-peptide analogue of GLP-1 with prolonged action <italic>in vivo</italic></article-title>. <source/>J. Am. Chem. Soc.
<volume>136</volume>, <fpage>12848</fpage>–<lpage>12851</lpage>. <pub-id pub-id-type="doi">10.1021/ja507168t</pub-id><pub-id pub-id-type="pmid">25191938</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirkpatrick</surname><given-names>A.</given-names></name><name><surname>Heo</surname><given-names>J.</given-names></name><name><surname>Abrol</surname><given-names>R.</given-names></name><name><surname>Goddard</surname><given-names>W. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class BG protein-coupled receptor</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>109</volume>, <fpage>19988</fpage>–<lpage>19993</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1218051109</pub-id><pub-id pub-id-type="pmid">23169631</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobilka</surname><given-names>B. K.</given-names></name><name><surname>Deupi</surname><given-names>X.</given-names></name></person-group> (<year>2007</year>). <article-title>Conformational complexity of G-protein-coupled receptors</article-title>. <source/>Trends Pharmacol. Sci.
<volume>28</volume>, <fpage>397</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2007.06.003</pub-id><pub-id pub-id-type="pmid">17629961</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koole</surname><given-names>C.</given-names></name><name><surname>Wootten</surname><given-names>D.</given-names></name><name><surname>Simms</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name><name><surname>Christopoulos</surname><given-names>A.</given-names></name><name><surname>Sexton</surname><given-names>P. M.</given-names></name></person-group> (<year>2012</year>). <article-title>Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) has a critical role in GLP-1 peptide binding and receptor activation</article-title>. <source/>J. Biol. Chem.
<volume>287</volume>, <fpage>3642</fpage>–<lpage>3658</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.309328</pub-id><pub-id pub-id-type="pmid">22147710</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koth</surname><given-names>C. M.</given-names></name><name><surname>Murray</surname><given-names>J. M.</given-names></name><name><surname>Mukund</surname><given-names>S.</given-names></name><name><surname>Madjidi</surname><given-names>A.</given-names></name><name><surname>Minn</surname><given-names>A.</given-names></name><name><surname>Clarke</surname><given-names>H. J.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Molecular basis for negative regulation of the glucagon receptor</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>109</volume>, <fpage>14393</fpage>–<lpage>14398</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1206734109</pub-id><pub-id pub-id-type="pmid">22908259</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>S.</given-names></name><name><surname>Pioszak</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>C. H.</given-names></name><name><surname>Swaminathan</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>H. E.</given-names></name></person-group> (<year>2011</year>). <article-title>Crystal structure of the PAC1R extracellular domain unifies a consensus fold for hormone recognition by Class B G-protein coupled receptors</article-title>. <source/>PLoS ONE
<volume>6</volume>:<fpage>e19682</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0019682</pub-id><pub-id pub-id-type="pmid">21625560</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusano</surname><given-names>S.</given-names></name><name><surname>Kukimoto-Niino</surname><given-names>M.</given-names></name><name><surname>Hino</surname><given-names>N.</given-names></name><name><surname>Ohsawa</surname><given-names>N.</given-names></name><name><surname>Okuda</surname><given-names>K.</given-names></name><name><surname>Sakamoto</surname><given-names>K.</given-names></name><etal></etal></person-group>. (<year>2012</year>). <article-title>Structural basis for extracellular interactions between calcitonin receptor-like receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding</article-title>. <source/>Protein Sci.
<volume>21</volume>, <fpage>199</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1002/pro.2003</pub-id><pub-id pub-id-type="pmid">22102369</pub-id></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lagerstrom</surname><given-names>M. C.</given-names></name><name><surname>Schioth</surname><given-names>H. B.</given-names></name></person-group> (<year>2008</year>). <article-title>Structural diversity of G protein-coupled receptors and significance for drug discovery</article-title>. <source/>Nat. Rev. Drug Discov.
<volume>7</volume>, <fpage>339</fpage>–<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1038/nrd2518</pub-id><pub-id pub-id-type="pmid">18382464</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langer</surname><given-names>I.</given-names></name><name><surname>Vertongen</surname><given-names>P.</given-names></name><name><surname>Perret</surname><given-names>J.</given-names></name><name><surname>Waelbroeck</surname><given-names>M.</given-names></name><name><surname>Robberecht</surname><given-names>P.</given-names></name></person-group> (<year>2002</year>). <article-title>A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector</article-title>. <source/>Mol. Endocrinol.
<volume>16</volume>, <fpage>1089</fpage>–<lpage>1096</lpage>. <pub-id pub-id-type="doi">10.1210/mend.16.5.0822</pub-id><pub-id pub-id-type="pmid">11981043</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leitz</surname><given-names>A. J.</given-names></name><name><surname>Bayburt</surname><given-names>T. H.</given-names></name><name><surname>Barnakov</surname><given-names>A. N.</given-names></name><name><surname>Springer</surname><given-names>B. A.</given-names></name><name><surname>Sligar</surname><given-names>S. G.</given-names></name></person-group> (<year>2006</year>). <article-title>Functional reconstitution of beta(2)-adrenergic receptors utilizing self-assembling Nanodisc technology</article-title>. <source/>Biotechniques
<volume>40</volume>, <fpage>601</fpage>–<lpage>602</lpage>. <pub-id pub-id-type="doi">10.2144/000112169</pub-id><pub-id pub-id-type="pmid">16708760</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liaw</surname><given-names>C. W.</given-names></name><name><surname>Grigoriadis</surname><given-names>D. E.</given-names></name><name><surname>Lovenberg</surname><given-names>T. W.</given-names></name><name><surname>De Souza</surname><given-names>E. B.</given-names></name><name><surname>Maki</surname><given-names>R. A.</given-names></name></person-group> (<year>1997</year>). <article-title>Localization of ligand-binding domains of human corticotropin-releasing factor receptor: a chimeric receptor approach</article-title>. <source/>Mol. Endocrinol.
<volume>11</volume>, <fpage>980</fpage>–<lpage>985</lpage>. <pub-id pub-id-type="doi">10.1210/mend.11.7.9946</pub-id><pub-id pub-id-type="pmid">9178757</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.-H.</given-names></name><name><surname>Rhoades</surname><given-names>E.</given-names></name><name><surname>Yan</surname><given-names>E. C. Y.</given-names></name></person-group> (<year>2015</year>). <article-title>Triblock peptide-linker-lipid molecular design improves potency of peptide ligands targeting family B G protein-coupled receptors</article-title>. <source/>Chem. Commun.
<volume>51</volume>, <fpage>6157</fpage>–<lpage>6160</lpage>. <pub-id pub-id-type="doi">10.1039/C5CC00301F</pub-id><pub-id pub-id-type="pmid">25748072</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Du</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name></person-group> (<year>2014</year>). <article-title>Toward fluorescent probes for G-Protein-Coupled Receptors (GPCRs)</article-title>. <source/>J. Med. Chem. <volume>57</volume>, <fpage>8187</fpage>–<lpage>8203</lpage>. <pub-id pub-id-type="doi">10.1021/jm401823z</pub-id><pub-id pub-id-type="pmid">24983484</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahalingam</surname><given-names>M.</given-names></name><name><surname>Martinez-Mayorga</surname><given-names>K.</given-names></name><name><surname>Brown</surname><given-names>M. F.</given-names></name><name><surname>Vogel</surname><given-names>R.</given-names></name></person-group> (<year>2008</year>). <article-title>Two protonation switches control rhodopsin activation in membranes</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>105</volume>, <fpage>17795</fpage>–<lpage>17800</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0804541105</pub-id><pub-id pub-id-type="pmid">18997017</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahon</surname><given-names>M. J.</given-names></name><name><surname>Donowitz</surname><given-names>M.</given-names></name><name><surname>Yun</surname><given-names>C. C.</given-names></name><name><surname>Segre</surname><given-names>G. V.</given-names></name></person-group> (<year>2002</year>). <article-title>Na(+)/H(+) exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling</article-title>. <source/>Nature
<volume>417</volume>, <fpage>858</fpage>–<lpage>861</lpage>. <pub-id pub-id-type="doi">10.1038/nature00816</pub-id><pub-id pub-id-type="pmid">12075354</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahon</surname><given-names>M. J.</given-names></name><name><surname>Segre</surname><given-names>G. V.</given-names></name></person-group> (<year>2004</year>). <article-title>Stimulation by parathyroid hormone of a NHERF-1-assembled complex consisting of the parathyroid hormone I receptor, phospholipase C beta, and actin increases intracellular calcium in opossum kidney cells</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>23550</fpage>–<lpage>23558</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M313229200</pub-id><pub-id pub-id-type="pmid">15037630</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahon</surname><given-names>M. J.</given-names></name><name><surname>Shimada</surname><given-names>M.</given-names></name></person-group> (<year>2005</year>). <article-title>Calmodulin interacts with the cytoplasmic tails of the parathyroid hormone 1 receptor and a sub-set of class b G-protein coupled receptors</article-title>. <source/>FEBS Lett.
<volume>579</volume>, <fpage>803</fpage>–<lpage>807</lpage>. <pub-id pub-id-type="doi">10.1016/j.febslet.2004.12.056</pub-id><pub-id pub-id-type="pmid">15670850</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannstadt</surname><given-names>M.</given-names></name><name><surname>Jüppner</surname><given-names>H.</given-names></name><name><surname>Gardella</surname><given-names>T. J.</given-names></name></person-group> (<year>1999</year>). <article-title>Receptors for PTH and PTHrP: their biological importance and functional properties</article-title>. <source/>Am. J. Physiol. Renal Physiol.
<volume>277</volume>, <fpage>F665</fpage>–<lpage>F675</lpage>. <pub-id pub-id-type="pmid">10564229</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathi</surname><given-names>S. K.</given-names></name><name><surname>Chan</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X. F.</given-names></name><name><surname>Wheeler</surname><given-names>M. B.</given-names></name></person-group> (<year>1997</year>). <article-title>Scanning of the glucagon-like peptide-1 receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop</article-title>. <source/>Mol. Endocrinol.
<volume>11</volume>, <fpage>424</fpage>–<lpage>432</lpage>. <pub-id pub-id-type="doi">10.1210/mend.11.4.9913</pub-id><pub-id pub-id-type="pmid">9092794</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLatchie</surname><given-names>L. M.</given-names></name><name><surname>Fraser</surname><given-names>N. J.</given-names></name><name><surname>Main</surname><given-names>M. J.</given-names></name><name><surname>Wise</surname><given-names>A.</given-names></name><name><surname>Brown</surname><given-names>J.</given-names></name><name><surname>Thompson</surname><given-names>N.</given-names></name><etal></etal></person-group>. (<year>1998</year>). <article-title>RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor</article-title>. <source/>Nature
<volume>393</volume>, <fpage>333</fpage>–<lpage>339</lpage>. <pub-id pub-id-type="doi">10.1038/30666</pub-id><pub-id pub-id-type="pmid">9620797</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>L. J.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Lam</surname><given-names>P. C.-H.</given-names></name><name><surname>Pinon</surname><given-names>D. I.</given-names></name><name><surname>Sexton</surname><given-names>P. M.</given-names></name><name><surname>Abagyan</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling</article-title>. <source/>J. Biol. Chem.
<volume>286</volume>, <fpage>15895</fpage>–<lpage>15907</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.217901</pub-id><pub-id pub-id-type="pmid">21454562</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>N.</given-names></name><name><surname>Liu</surname><given-names>Y. T.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Serebryany</surname><given-names>E.</given-names></name><name><surname>Mooney</surname><given-names>V.</given-names></name><name><surname>Devree</surname><given-names>B. T.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Calcium-dependent ligand binding and G-protein signaling of family B GPCR parathyroid hormone 1 receptor purified in nanodiscs</article-title>. <source/>ACS Chem. Biol.
<volume>8</volume>, <fpage>617</fpage>–<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1021/cb300466n</pub-id><pub-id pub-id-type="pmid">23237450</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>I. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Structural features of the G-protein/GPCR interactions</article-title>. <source/>Biochim. Biophys. Acta
<volume>1840</volume>, <fpage>16</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2013.08.027</pub-id><pub-id pub-id-type="pmid">24016604</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukund</surname><given-names>S.</given-names></name><name><surname>Shang</surname><given-names>Y. L.</given-names></name><name><surname>Clarke</surname><given-names>H. J.</given-names></name><name><surname>Madjidi</surname><given-names>A.</given-names></name><name><surname>Corn</surname><given-names>J. E.</given-names></name><name><surname>Kates</surname><given-names>L.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Inhibitory mechanism of an allosteric antibody targeting the glucagon receptor</article-title>. <source/>J. Biol. Chem.
<volume>288</volume>, <fpage>36168</fpage>–<lpage>36178</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M113.496984</pub-id><pub-id pub-id-type="pmid">24189067</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neumann</surname><given-names>J.-M.</given-names></name><name><surname>Couvineau</surname><given-names>A.</given-names></name><name><surname>Murail</surname><given-names>S.</given-names></name><name><surname>Lacapère</surname><given-names>J.-J.</given-names></name><name><surname>Jamin</surname><given-names>N.</given-names></name><name><surname>Laburthe</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Class-B GPCR activation: is ligand helix-capping the key?</article-title>
<source/>Trends Biochem. Sci.
<volume>33</volume>, <fpage>314</fpage>–<lpage>319</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2008.05.001</pub-id><pub-id pub-id-type="pmid">18555686</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicole</surname><given-names>P.</given-names></name><name><surname>Lins</surname><given-names>L.</given-names></name><name><surname>Rouyer-Fessard</surname><given-names>C.</given-names></name><name><surname>Drouot</surname><given-names>C.</given-names></name><name><surname>Fulcrand</surname><given-names>P.</given-names></name><name><surname>Thomas</surname><given-names>A.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>Identification of key residues for interaction of vasoactive intestinal peptide with human VPAC1 and VPAC2 receptors and development of a highly selective VPAC1 receptor agonist: alanine scanning and molecular modeling of the peptide</article-title>. <source/>J. Biol. Chem.
<volume>275</volume>, <fpage>24003</fpage>–<lpage>24012</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M002325200</pub-id><pub-id pub-id-type="pmid">10801840</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohtaki</surname><given-names>T.</given-names></name><name><surname>Ogi</surname><given-names>K.</given-names></name><name><surname>Masuda</surname><given-names>Y.</given-names></name><name><surname>Mitsuoka</surname><given-names>K.</given-names></name><name><surname>Fujiyoshi</surname><given-names>Y.</given-names></name><name><surname>Kitada</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>1998</year>). <article-title>Expression, purification, and reconstitution of receptor for pituitary adenylate cyclase-activating polypeptide large-scale purification of a functionally active G protein-coupled receptor produced in SF9 insect cells</article-title>. <source/>J. Biol. Chem.
<volume>273</volume>, <fpage>15464</fpage>–<lpage>15473</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.273.25.15464</pub-id><pub-id pub-id-type="pmid">9624132</pub-id></mixed-citation>
</ref>
<ref id="B106">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>T.</given-names></name><name><surname>Sugihara</surname><given-names>M.</given-names></name><name><surname>Bondar</surname><given-names>A. N.</given-names></name><name><surname>Elstner</surname><given-names>M.</given-names></name><name><surname>Entel</surname><given-names>P.</given-names></name><name><surname>Buss</surname><given-names>V.</given-names></name></person-group> (<year>2004</year>). <article-title>The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure</article-title>. <source/>J. Mol. Biol.
<volume>342</volume>, <fpage>571</fpage>–<lpage>583</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2004.07.044</pub-id><pub-id pub-id-type="pmid">15327956</pub-id></mixed-citation>
</ref>
<ref id="B107">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>M.</given-names></name><name><surname>Ferrandon</surname><given-names>S.</given-names></name><name><surname>Vilardaga</surname><given-names>J. P.</given-names></name><name><surname>Bouxsein</surname><given-names>M. L.</given-names></name><name><surname>Potts</surname><given-names>J. T.</given-names></name><name><surname>Gardella</surname><given-names>T. J.</given-names></name></person-group> (<year>2008</year>). <article-title>Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation (vol 105, pg 16525, 2008)</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>105</volume>, <fpage>20559</fpage>–<lpage>20559</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0808750105</pub-id></mixed-citation>
</ref>
<ref id="B108">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>K.</given-names></name><name><surname>Melcher</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>H. E.</given-names></name></person-group> (<year>2012</year>). <article-title>Structure and mechanism for recognition of peptide hormones by Class B G protein coupled receptors</article-title>. <source/>Acta Pharmacol. Sin.
<volume>33</volume>, <fpage>300</fpage>–<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1038/aps.2011.170</pub-id><pub-id pub-id-type="pmid">22266723</pub-id></mixed-citation>
</ref>
<ref id="B109">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>K.</given-names></name><name><surname>Swaminathan</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>H. E.</given-names></name><name><surname>Pioszak</surname><given-names>A. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Structural basis for hormone recognition by the human CRFR2 alpha G Protein-coupled Receptor</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>40351</fpage>–<lpage>40361</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.186072</pub-id><pub-id pub-id-type="pmid">20966082</pub-id></mixed-citation>
</ref>
<ref id="B110">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palczewski</surname><given-names>K.</given-names></name><name><surname>Kumasaka</surname><given-names>T.</given-names></name><name><surname>Hori</surname><given-names>T.</given-names></name><name><surname>Behnke</surname><given-names>C. A.</given-names></name><name><surname>Motoshima</surname><given-names>H.</given-names></name><name><surname>Fox</surname><given-names>B. A.</given-names></name><etal></etal></person-group>. (<year>2000</year>). <article-title>Crystal structure of rhodopsin: AG protein-coupled receptor</article-title>. <source/>Science
<volume>289</volume>, <fpage>739</fpage>–<lpage>745</lpage>. <pub-id pub-id-type="doi">10.1126/science.289.5480.739</pub-id><pub-id pub-id-type="pmid">10926528</pub-id></mixed-citation>
</ref>
<ref id="B111">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>D.</given-names></name><name><surname>Ganim</surname><given-names>Z.</given-names></name><name><surname>Kim</surname><given-names>J. E.</given-names></name><name><surname>Verhoeven</surname><given-names>M. A.</given-names></name><name><surname>Lugtenburg</surname><given-names>J.</given-names></name><name><surname>Mathies</surname><given-names>R. A.</given-names></name></person-group> (<year>2002</year>). <article-title>Time-resolved resonance Raman analysis of chromophore structural changes in the formation and decay of rhodopsin's BSI intermediate</article-title>. <source/>J. Am. Chem. Soc.
<volume>124</volume>, <fpage>4857</fpage>–<lpage>4864</lpage>. <pub-id pub-id-type="doi">10.1021/ja012666e</pub-id><pub-id pub-id-type="pmid">11971736</pub-id></mixed-citation>
</ref>
<ref id="B112">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parameswaran</surname><given-names>N.</given-names></name><name><surname>Spielman</surname><given-names>W. S.</given-names></name></person-group> (<year>2006</year>). <article-title>RAMPs: the past, present and future</article-title>. <source/>Trends Biochem. Sci.
<volume>31</volume>, <fpage>631</fpage>–<lpage>638</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2006.09.006</pub-id><pub-id pub-id-type="pmid">17010614</pub-id></mixed-citation>
</ref>
<ref id="B113">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parthier</surname><given-names>C.</given-names></name><name><surname>Kleinschmidt</surname><given-names>M.</given-names></name><name><surname>Neumann</surname><given-names>P.</given-names></name><name><surname>Rudolph</surname><given-names>R.</given-names></name><name><surname>Manhart</surname><given-names>S.</given-names></name><name><surname>Schlenzig</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>104</volume>, <fpage>13942</fpage>–<lpage>13947</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0706404104</pub-id><pub-id pub-id-type="pmid">17715056</pub-id></mixed-citation>
</ref>
<ref id="B114">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parthier</surname><given-names>C.</given-names></name><name><surname>Reedtz-Runge</surname><given-names>S.</given-names></name><name><surname>Rudolph</surname><given-names>R.</given-names></name><name><surname>Stubbs</surname><given-names>M. T.</given-names></name></person-group> (<year>2009</year>). <article-title>Passing the baton in class B GPCRs: peptide hormone activation via helix induction?</article-title>
<source/>Trends Biochem. Sci.
<volume>34</volume>, <fpage>303</fpage>–<lpage>310</lpage>. <pub-id pub-id-type="doi">10.1016/j.tibs.2009.02.004</pub-id><pub-id pub-id-type="pmid">19446460</pub-id></mixed-citation>
</ref>
<ref id="B115">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perret</surname><given-names>J.</given-names></name><name><surname>Craenenbroeck</surname><given-names>M.</given-names></name><name><surname>Langer</surname><given-names>I.</given-names></name><name><surname>Vertongen</surname><given-names>P.</given-names></name><name><surname>Gregoire</surname><given-names>F.</given-names></name><name><surname>Robberecht</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2002</year>). <article-title>Mutational analysis of the glucagon receptor: similarities with the vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide (PACAP)/secretin receptors for recognition of the ligand's third residue</article-title>. <source/>Biochem. J.
<volume>362</volume>, <fpage>389</fpage>–<lpage>394</lpage>. <pub-id pub-id-type="doi">10.1042/bj3620389</pub-id><pub-id pub-id-type="pmid">11853547</pub-id></mixed-citation>
</ref>
<ref id="B116">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>V.</given-names></name><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Wade</surname><given-names>J. D.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name><name><surname>Morton</surname><given-names>C. J.</given-names></name><name><surname>Ng</surname><given-names>H.-L.</given-names></name><etal></etal></person-group>. (<year>2005</year>). <article-title>Insights into interactions between the α-Helical region of the salmon calcitonin antagonists and the human calcitonin receptor using photoaffinity labeling</article-title>. <source/>J. Biol. Chem.
<volume>280</volume>, <fpage>28610</fpage>–<lpage>28622</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M503272200</pub-id><pub-id pub-id-type="pmid">15929987</pub-id></mixed-citation>
</ref>
<ref id="B117">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pham</surname><given-names>V.</given-names></name><name><surname>Wade</surname><given-names>J. D.</given-names></name><name><surname>Purdue</surname><given-names>B. W.</given-names></name><name><surname>Sexton</surname><given-names>P. M.</given-names></name></person-group> (<year>2004</year>). <article-title>Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor</article-title>. <source/>J. Biol. Chem.
<volume>279</volume>, <fpage>6720</fpage>–<lpage>6729</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M307214200</pub-id><pub-id pub-id-type="pmid">14623894</pub-id></mixed-citation>
</ref>
<ref id="B118">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pioszak</surname><given-names>A. A.</given-names></name><name><surname>Harikumar</surname><given-names>K. G.</given-names></name><name><surname>Parker</surname><given-names>N. R.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name><name><surname>Xu</surname><given-names>H. E.</given-names></name></person-group> (<year>2010</year>). <article-title>Dimeric arrangement of the parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>12435</fpage>–<lpage>12444</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.093138</pub-id><pub-id pub-id-type="pmid">20172855</pub-id></mixed-citation>
</ref>
<ref id="B119">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pioszak</surname><given-names>A. A.</given-names></name><name><surname>Parker</surname><given-names>N. R.</given-names></name><name><surname>Gardella</surname><given-names>T. J.</given-names></name><name><surname>Xu</surname><given-names>H. E.</given-names></name></person-group> (<year>2009</year>). <article-title>Structural basis for parathyroid hormone-related protein binding to the parathyroid hormone receptor and design of conformation-selective peptides</article-title>. <source/>J. Biol. Chem.
<volume>284</volume>, <fpage>28382</fpage>–<lpage>28391</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.022905</pub-id><pub-id pub-id-type="pmid">19674967</pub-id></mixed-citation>
</ref>
<ref id="B120">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pioszak</surname><given-names>A. A.</given-names></name><name><surname>Parker</surname><given-names>N. R.</given-names></name><name><surname>Suino-Powell</surname><given-names>K.</given-names></name><name><surname>Xu</surname><given-names>H. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Molecular recognition of corticotropin-releasing factor by its G-protein-coupled Receptor CRFR1</article-title>. <source/>J. Biol. Chem.
<volume>283</volume>, <fpage>32900</fpage>–<lpage>32912</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M805749200</pub-id><pub-id pub-id-type="pmid">18801728</pub-id></mixed-citation>
</ref>
<ref id="B121">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pioszak</surname><given-names>A. A.</given-names></name><name><surname>Xu</surname><given-names>H. E.</given-names></name></person-group> (<year>2008</year>). <article-title>Molecular recognition of parathyroid hormone by its G protein-coupled receptor</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>105</volume>, <fpage>5034</fpage>–<lpage>5039</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0801027105</pub-id><pub-id pub-id-type="pmid">18375760</pub-id></mixed-citation>
</ref>
<ref id="B122">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prévost</surname><given-names>M.</given-names></name><name><surname>Vertongen</surname><given-names>P.</given-names></name><name><surname>Raussens</surname><given-names>V.</given-names></name><name><surname>Roberts</surname><given-names>D. J.</given-names></name><name><surname>Cnudde</surname><given-names>J.</given-names></name><name><surname>Perret</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Mutational and cysteine scanning analysis of the glucagon receptor N-terminal domain</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>30951</fpage>–<lpage>30958</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.102814</pub-id><pub-id pub-id-type="pmid">20647307</pub-id></mixed-citation>
</ref>
<ref id="B123">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prioleau</surname><given-names>C.</given-names></name><name><surname>Visiers</surname><given-names>I.</given-names></name><name><surname>Ebersole</surname><given-names>B. J.</given-names></name><name><surname>Weinstein</surname><given-names>H.</given-names></name><name><surname>Sealfon</surname><given-names>S. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Conserved Helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor identification of a novel “locked-on” phenotype and double revertant mutations</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>36577</fpage>–<lpage>36584</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M206223200</pub-id><pub-id pub-id-type="pmid">12145300</pub-id></mixed-citation>
</ref>
<ref id="B124">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>T.</given-names></name><name><surname>Hay</surname><given-names>D. L.</given-names></name></person-group> (<year>2010</year>). <article-title>Structure–function relationships of the N-terminus of receptor activity-modifying proteins</article-title>. <source/>Br. J. Pharmacol.
<volume>159</volume>, <fpage>1059</fpage>–<lpage>1068</lpage>. <pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00541.x</pub-id><pub-id pub-id-type="pmid">20015292</pub-id></mixed-citation>
</ref>
<ref id="B125">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>K.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Wu</surname><given-names>G.</given-names></name><name><surname>Lambert</surname><given-names>N. A.</given-names></name></person-group> (<year>2011</year>). <article-title>Inactive-state preassembly of Gq-coupled receptors and Gq heterotrimers</article-title>. <source/>Nat. Chem. Biol.
<volume>7</volume>, <fpage>740</fpage>–<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.642</pub-id><pub-id pub-id-type="pmid">21873996</pub-id></mixed-citation>
</ref>
<ref id="B126">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rashid</surname><given-names>A. J.</given-names></name><name><surname>O'dowd</surname><given-names>B. F.</given-names></name><name><surname>George</surname><given-names>S. R.</given-names></name></person-group> (<year>2004</year>). <article-title>Minireview: diversity and complexity of signaling through peptidergic G protein-coupled receptors</article-title>. <source/>Endocrinology
<volume>145</volume>, <fpage>2645</fpage>–<lpage>2652</lpage>. <pub-id pub-id-type="doi">10.1210/en.2004-0052</pub-id><pub-id pub-id-type="pmid">15044354</pub-id></mixed-citation>
</ref>
<ref id="B127">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>S. G. F.</given-names></name><name><surname>Devree</surname><given-names>B. T.</given-names></name><name><surname>Zou</surname><given-names>Y.</given-names></name><name><surname>Kruse</surname><given-names>A. C.</given-names></name><name><surname>Chung</surname><given-names>K. Y.</given-names></name><name><surname>Kobilka</surname><given-names>T. S.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Crystal structure of the [bgr]2 adrenergic receptor-Gs protein complex</article-title>. <source/>Nature
<volume>477</volume>, <fpage>549</fpage>–<lpage>555</lpage>. <pub-id pub-id-type="doi">10.1038/nature10361</pub-id><pub-id pub-id-type="pmid">21772288</pub-id></mixed-citation>
</ref>
<ref id="B128">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravn</surname><given-names>P.</given-names></name><name><surname>Madhurantakam</surname><given-names>C.</given-names></name><name><surname>Kunze</surname><given-names>S.</given-names></name><name><surname>Matthews</surname><given-names>E.</given-names></name><name><surname>Priest</surname><given-names>C.</given-names></name><name><surname>O'brien</surname><given-names>S.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor</article-title>. <source/>J. Biol. Chem.
<volume>288</volume>, <fpage>19760</fpage>–<lpage>19772</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M112.426288</pub-id><pub-id pub-id-type="pmid">23689510</pub-id></mixed-citation>
</ref>
<ref id="B129">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritter</surname><given-names>S. L.</given-names></name><name><surname>Hall</surname><given-names>R. A.</given-names></name></person-group> (<year>2009</year>). <article-title>Fine-tuning of GPCR activity by receptor-interacting proteins</article-title>. <source/>Nat. Rev. Mol. Cell Biol.
<volume>10</volume>, <fpage>819</fpage>–<lpage>830</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2803</pub-id><pub-id pub-id-type="pmid">19935667</pub-id></mixed-citation>
</ref>
<ref id="B130">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>D. J.</given-names></name><name><surname>Vertongen</surname><given-names>P.</given-names></name><name><surname>Waelbroeck</surname><given-names>M.</given-names></name></person-group> (<year>2011</year>). <article-title>Analysis of the glucagon receptor first extracellular loop by the substituted cysteine accessibility method</article-title>. <source/>Peptides
<volume>32</volume>, <fpage>1593</fpage>–<lpage>1599</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2011.06.009</pub-id><pub-id pub-id-type="pmid">21704096</pub-id></mixed-citation>
</ref>
<ref id="B131">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roed</surname><given-names>S. N.</given-names></name><name><surname>Orgaard</surname><given-names>A.</given-names></name><name><surname>Jorgensen</surname><given-names>R.</given-names></name><name><surname>De Meyts</surname><given-names>P.</given-names></name></person-group> (<year>2012</year>). <article-title>Receptor oligomerization in family B1 of G-protein-coupled receptors: focus on BRET investigations and the link between GPCR oligomerization and binding cooperativity</article-title>. <source/>Front. Endocrinol.
<volume>3</volume>:<issue>62</issue>. <pub-id pub-id-type="doi">10.3389/fendo.2012.00062</pub-id><pub-id pub-id-type="pmid">22649424</pub-id></mixed-citation>
</ref>
<ref id="B132">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Runge</surname><given-names>S.</given-names></name><name><surname>Gram</surname><given-names>C.</given-names></name><name><surname>Brauner-Osborne</surname><given-names>H.</given-names></name><name><surname>Madsen</surname><given-names>K.</given-names></name><name><surname>Knudsen</surname><given-names>L. B.</given-names></name><name><surname>Wulff</surname><given-names>B. S.</given-names></name></person-group> (<year>2003</year>). <article-title>Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>28005</fpage>–<lpage>28010</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M301085200</pub-id><pub-id pub-id-type="pmid">12724331</pub-id></mixed-citation>
</ref>
<ref id="B133">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Runge</surname><given-names>S.</given-names></name><name><surname>Thogersen</surname><given-names>H.</given-names></name><name><surname>Madsen</surname><given-names>K.</given-names></name><name><surname>Lau</surname><given-names>J.</given-names></name><name><surname>Rudolph</surname><given-names>R.</given-names></name></person-group> (<year>2008</year>). <article-title>Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain</article-title>. <source/>J. Biol. Chem.
<volume>283</volume>, <fpage>11340</fpage>–<lpage>11347</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M708740200</pub-id><pub-id pub-id-type="pmid">18287102</pub-id></mixed-citation>
</ref>
<ref id="B134">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheerer</surname><given-names>P.</given-names></name><name><surname>Park</surname><given-names>J. H.</given-names></name><name><surname>Hildebrand</surname><given-names>P. W.</given-names></name><name><surname>Kim</surname><given-names>Y. J.</given-names></name><name><surname>Krauss</surname><given-names>N.</given-names></name><name><surname>Choe</surname><given-names>H.-W.</given-names></name><etal></etal></person-group>. (<year>2008</year>). <article-title>Crystal structure of opsin in its G-protein-interacting conformation</article-title>. <source/>Nature
<volume>455</volume>, <fpage>497</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1038/nature07330</pub-id><pub-id pub-id-type="pmid">18818650</pub-id></mixed-citation>
</ref>
<ref id="B135">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schipani</surname><given-names>E.</given-names></name><name><surname>Jensen</surname><given-names>G. S.</given-names></name><name><surname>Pincus</surname><given-names>J.</given-names></name><name><surname>Nissenson</surname><given-names>R. A.</given-names></name><name><surname>Gardella</surname><given-names>T. J.</given-names></name><name><surname>Jüppner</surname><given-names>H.</given-names></name></person-group> (<year>1997</year>). <article-title>Constitutive activation of the cyclic adenosine 3',5'-monophosphate signaling pathway by parathyroid hormone (PTH)/PTH-related peptide receptors mutated at the two loci for Jansen's metaphyseal chondrodysplasia</article-title>. <source/>Mol. Endocrinol.
<volume>11</volume>, <fpage>851</fpage>–<lpage>858</lpage>. <pub-id pub-id-type="pmid">9178745</pub-id></mixed-citation>
</ref>
<ref id="B136">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schipani</surname><given-names>E.</given-names></name><name><surname>Kruse</surname><given-names>K.</given-names></name><name><surname>Jüppner</surname><given-names>H.</given-names></name></person-group> (<year>1995</year>). <article-title>A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia</article-title>. <source/>Science
<volume>268</volume>, <fpage>98</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1126/science.7701349</pub-id><pub-id pub-id-type="pmid">7701349</pub-id></mixed-citation>
</ref>
<ref id="B137">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serebryany</surname><given-names>E.</given-names></name><name><surname>Zhu</surname><given-names>G. A.</given-names></name><name><surname>Yan</surname><given-names>E. C. Y.</given-names></name></person-group> (<year>2012</year>). <article-title>Artificial membrane-like environments for <italic>in vitro</italic> studies of purified G-protein coupled receptors</article-title>. <source/>Biochim. Biophys. Acta
<volume>1818</volume>, <fpage>225</fpage>–<lpage>233</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamem.2011.07.047</pub-id><pub-id pub-id-type="pmid">21851807</pub-id></mixed-citation>
</ref>
<ref id="B138">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>D. A.</given-names></name><name><surname>Kristiansen</surname><given-names>K.</given-names></name><name><surname>Weiner</surname><given-names>D. M.</given-names></name><name><surname>Kroeze</surname><given-names>W. K.</given-names></name><name><surname>Roth</surname><given-names>B. L.</given-names></name></person-group> (<year>2002</year>). <article-title>Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>11441</fpage>–<lpage>11449</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111675200</pub-id><pub-id pub-id-type="pmid">11801601</pub-id></mixed-citation>
</ref>
<ref id="B139">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimada</surname><given-names>M.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Cvrk</surname><given-names>T.</given-names></name><name><surname>Hilfiker</surname><given-names>H.</given-names></name><name><surname>Parfenova</surname><given-names>M.</given-names></name><name><surname>Segre</surname><given-names>G. V.</given-names></name></person-group> (<year>2002</year>). <article-title>Purification and characterization of a receptor for human parathyroid hormone and parathyroid hormone-related peptide</article-title>. <source/>J. Biol. Chem.
<volume>277</volume>, <fpage>31774</fpage>–<lpage>31780</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M204166200</pub-id><pub-id pub-id-type="pmid">12080067</pub-id></mixed-citation>
</ref>
<ref id="B140">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimamura</surname><given-names>T.</given-names></name><name><surname>Shiroishi</surname><given-names>M.</given-names></name><name><surname>Weyand</surname><given-names>S.</given-names></name><name><surname>Tsujimoto</surname><given-names>H.</given-names></name><name><surname>Winter</surname><given-names>G.</given-names></name><name><surname>Katritch</surname><given-names>V.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>Structure of the human histamine H1 receptor complex with doxepin</article-title>. <source/>Nature
<volume>475</volume>, <fpage>65</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1038/nature10236</pub-id><pub-id pub-id-type="pmid">21697825</pub-id></mixed-citation>
</ref>
<ref id="B141">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>R.</given-names></name><name><surname>Ahalawat</surname><given-names>N.</given-names></name><name><surname>Murarka</surname><given-names>R. K.</given-names></name></person-group> (<year>2015</year>). <article-title>Activation of corticotropin-releasing factor 1 receptor: insights from molecular dynamics simulations</article-title>. <source/>J. Phys. Chem. B
<volume>119</volume>, <fpage>2806</fpage>–<lpage>2817</lpage>. <pub-id pub-id-type="doi">10.1021/jp509814n</pub-id><pub-id pub-id-type="pmid">25607803</pub-id></mixed-citation>
</ref>
<ref id="B142">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>A.</given-names></name><name><surname>Ostermaier</surname><given-names>M. K.</given-names></name><name><surname>Vishnivetskiy</surname><given-names>S. A.</given-names></name><name><surname>Panneels</surname><given-names>V.</given-names></name><name><surname>Homan</surname><given-names>K. T.</given-names></name><name><surname>Tesmer</surname><given-names>J. J.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Insights into congenital stationary night blindness based on the structure of G90D rhodopsin</article-title>. <source/>EMBO Rep.
<volume>14</volume>, <fpage>520</fpage>–<lpage>526</lpage>. <pub-id pub-id-type="doi">10.1038/embor.2013.44</pub-id><pub-id pub-id-type="pmid">23579341</pub-id></mixed-citation>
</ref>
<ref id="B143">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siu</surname><given-names>F. Y.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name><name><surname>De Graaf</surname><given-names>C.</given-names></name><name><surname>Han</surname><given-names>G. W.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Structure of the human glucagon class B G-protein-coupled receptor</article-title>. <source/>Nature
<volume>449</volume>, <fpage>444</fpage>–<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1038/nature12393</pub-id><pub-id pub-id-type="pmid">23863937</pub-id></mixed-citation>
</ref>
<ref id="B144">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>S. O.</given-names></name></person-group> (<year>2010</year>). <article-title>Structure and activation of the visual pigment rhodopsin</article-title>. <source/>Annu. Rev. Biophys.
<volume>39</volume>, <fpage>309</fpage>–<lpage>328</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-biophys-101209-104901</pub-id><pub-id pub-id-type="pmid">20192770</pub-id></mixed-citation>
</ref>
<ref id="B145">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solano</surname><given-names>R. M.</given-names></name><name><surname>Langer</surname><given-names>I.</given-names></name><name><surname>Perret</surname><given-names>J.</given-names></name><name><surname>Vertongen</surname><given-names>P.</given-names></name><name><surname>Juarranz</surname><given-names>M. G.</given-names></name><name><surname>Robberecht</surname><given-names>P.</given-names></name><etal></etal></person-group>. (<year>2001</year>). <article-title>Two basic residues of the h-VPAC1 receptor second transmembrane helix are essential for ligand binding and signal transduction</article-title>. <source/>J. Biol. Chem.
<volume>276</volume>, <fpage>1084</fpage>–<lpage>1088</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M007686200</pub-id><pub-id pub-id-type="pmid">11013258</pub-id></mixed-citation>
</ref>
<ref id="B146">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Standfuss</surname><given-names>J.</given-names></name><name><surname>Edwards</surname><given-names>P. C.</given-names></name><name><surname>D'antona</surname><given-names>A.</given-names></name><name><surname>Fransen</surname><given-names>M.</given-names></name><name><surname>Xie</surname><given-names>G.</given-names></name><name><surname>Oprian</surname><given-names>D. D.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>The structural basis of agonist-induced activation in constitutively active rhodopsin</article-title>. <source/>Nature
<volume>471</volume>, <fpage>656</fpage>–<lpage>660</lpage>. <pub-id pub-id-type="doi">10.1038/nature09795</pub-id><pub-id pub-id-type="pmid">21389983</pub-id></mixed-citation>
</ref>
<ref id="B147">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname><given-names>R. C.</given-names></name><name><surname>Cherezov</surname><given-names>V.</given-names></name><name><surname>Katritch</surname><given-names>V.</given-names></name><name><surname>Abagyan</surname><given-names>R.</given-names></name><name><surname>Kuhn</surname><given-names>P.</given-names></name><name><surname>Rosen</surname><given-names>H.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>The GPCR Network: a large-scale collaboration to determine human GPCR structure and function</article-title>. <source/>Nat. Rev. Drug Discov.
<volume>12</volume>, <fpage>25</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1038/nrd3859</pub-id><pub-id pub-id-type="pmid">23237917</pub-id></mixed-citation>
</ref>
<ref id="B148">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>C.</given-names></name><name><surname>Song</surname><given-names>D.</given-names></name><name><surname>Davis-Taber</surname><given-names>R. A.</given-names></name><name><surname>Barrett</surname><given-names>L. W.</given-names></name><name><surname>Scott</surname><given-names>V. E.</given-names></name><name><surname>Richardson</surname><given-names>P. L.</given-names></name><etal></etal></person-group>. (<year>2007</year>). <article-title>Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>104</volume>, <fpage>7875</fpage>–<lpage>7880</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0611397104</pub-id><pub-id pub-id-type="pmid">17470806</pub-id></mixed-citation>
</ref>
<ref id="B149">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takhar</surname><given-names>S.</given-names></name><name><surname>Gyomorey</surname><given-names>S.</given-names></name><name><surname>Su</surname><given-names>R. C.</given-names></name><name><surname>Mathi</surname><given-names>S. K.</given-names></name><name><surname>Li</surname><given-names>X. F.</given-names></name><name><surname>Wheeler</surname><given-names>M. B.</given-names></name></person-group> (<year>1996</year>). <article-title>The third cytoplasmic domain of the GLP-1[7-36 amide] receptor is required for coupling to the adenylyl cyclase system</article-title>. <source/>Endocrinology
<volume>137</volume>, <fpage>2175</fpage>–<lpage>2178</lpage>. <pub-id pub-id-type="pmid">8612565</pub-id></mixed-citation>
</ref>
<ref id="B150">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Y.-V.</given-names></name><name><surname>Couvineau</surname><given-names>A.</given-names></name><name><surname>Murail</surname><given-names>S.</given-names></name><name><surname>Ceraudo</surname><given-names>E.</given-names></name><name><surname>Neumann</surname><given-names>J.-M.</given-names></name><name><surname>Lacapère</surname><given-names>J.-J.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Peptide agonist docking in the N-terminal ectodomain of a Class II G protein-coupled receptor, the VPAC1 receptor photoaffinity, NMR, and molecular modeling</article-title>. <source/>J. Biol. Chem.
<volume>281</volume>, <fpage>12792</fpage>–<lpage>12798</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M513305200</pub-id><pub-id pub-id-type="pmid">16520374</pub-id></mixed-citation>
</ref>
<ref id="B151">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>Y.-V.</given-names></name><name><surname>Couvineau</surname><given-names>A.</given-names></name><name><surname>Van Rampelbergh</surname><given-names>J.</given-names></name><name><surname>Laburthe</surname><given-names>M.</given-names></name></person-group> (<year>2003</year>). <article-title>Photoaffinity labeling demonstrates physical contact between vasoactive intestinal peptide and the N-terminal ectodomain of the human VPAC1 receptor</article-title>. <source/>J. Biol. Chem.
<volume>278</volume>, <fpage>36531</fpage>–<lpage>36536</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M304770200</pub-id><pub-id pub-id-type="pmid">12807902</pub-id></mixed-citation>
</ref>
<ref id="B152">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tautermann</surname><given-names>C. S.</given-names></name></person-group> (<year>2014</year>). <article-title>GPCR structures in drug design, emerging opportunities with new structures</article-title>. <source/>Bioorg. Med. Chem. Lett.
<volume>24</volume>, <fpage>4073</fpage>–<lpage>4079</lpage>. <pub-id pub-id-type="doi">10.1016/j.bmcl.2014.07.009</pub-id><pub-id pub-id-type="pmid">25086683</pub-id></mixed-citation>
</ref>
<ref id="B153">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tehan</surname><given-names>B. G.</given-names></name><name><surname>Bortolato</surname><given-names>A.</given-names></name><name><surname>Blaney</surname><given-names>F. E.</given-names></name><name><surname>Weir</surname><given-names>M. P.</given-names></name><name><surname>Mason</surname><given-names>J. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Unifying family A GPCR theories of activation</article-title>. <source/>Pharmacol. Ther.
<volume>143</volume>, <fpage>51</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.02.004</pub-id><pub-id pub-id-type="pmid">24561131</pub-id></mixed-citation>
</ref>
<ref id="B154">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ter Haar</surname><given-names>E.</given-names></name><name><surname>Koth</surname><given-names>C. M.</given-names></name><name><surname>Abdul-Manan</surname><given-names>N.</given-names></name><name><surname>Swenson</surname><given-names>L.</given-names></name><name><surname>Coll</surname><given-names>J. T.</given-names></name><name><surname>Lippke</surname><given-names>J. A.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Crystal structure of the ectodomain complex of the CGRP receptor, a Class-B GPCR, reveals the site of drug antagonism</article-title>. <source/>Structure
<volume>18</volume>, <fpage>1083</fpage>–<lpage>1093</lpage>. <pub-id pub-id-type="doi">10.1016/j.str.2010.05.014</pub-id><pub-id pub-id-type="pmid">20826335</pub-id></mixed-citation>
</ref>
<ref id="B155">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>B. E.</given-names></name><name><surname>Woznica</surname><given-names>I.</given-names></name><name><surname>Mierke</surname><given-names>D. F.</given-names></name><name><surname>Wittelsberger</surname><given-names>A.</given-names></name><name><surname>Rosenblatt</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>). <article-title>Conformational changes in the parathyroid hormone receptor associated with activation by agonist</article-title>. <source/>Mol. Endocrinol.
<volume>22</volume>, <fpage>1154</fpage>–<lpage>1162</lpage>. <pub-id pub-id-type="doi">10.1210/me.2007-0520</pub-id><pub-id pub-id-type="pmid">18258686</pub-id></mixed-citation>
</ref>
<ref id="B156">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>C. C.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name></person-group> (<year>1997</year>). <article-title>A point mutation in the glucose-dependent insulinotropic peptide receptor confers constitutive activity</article-title>. <source/>Biochem. Biophys. Res. Commun.
<volume>232</volume>, <fpage>96</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1006/bbrc.1997.6231</pub-id><pub-id pub-id-type="pmid">9125160</pub-id></mixed-citation>
</ref>
<ref id="B157">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Underwood</surname><given-names>C. R.</given-names></name><name><surname>Garibay</surname><given-names>P.</given-names></name><name><surname>Knudsen</surname><given-names>L. B.</given-names></name><name><surname>Hastrup</surname><given-names>S.</given-names></name><name><surname>Peters</surname><given-names>G. H.</given-names></name><name><surname>Rudolph</surname><given-names>R.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Crystal structure of Glucagon-like Peptide-1 in complex with the extracellular domain of the Glucagon-like Peptide-1 receptor</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>723</fpage>–<lpage>730</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M109.033829</pub-id><pub-id pub-id-type="pmid">19861722</pub-id></mixed-citation>
</ref>
<ref id="B158">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Unson</surname><given-names>C. G.</given-names></name><name><surname>Wu</surname><given-names>C.-R.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name><name><surname>Yoo</surname><given-names>B.</given-names></name><name><surname>Cheung</surname><given-names>C.</given-names></name><name><surname>Sakmar</surname><given-names>T. P.</given-names></name><etal></etal></person-group>. (<year>2002</year>). <article-title>Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling†</article-title>. <source/>Biochemistry
<volume>41</volume>, <fpage>11795</fpage>–<lpage>11803</lpage>. <pub-id pub-id-type="doi">10.1021/bi025711j</pub-id><pub-id pub-id-type="pmid">12269822</pub-id></mixed-citation>
</ref>
<ref id="B159">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilardaga</surname><given-names>J. P.</given-names></name><name><surname>Bunemann</surname><given-names>M.</given-names></name><name><surname>Krasel</surname><given-names>C.</given-names></name><name><surname>Castro</surname><given-names>M.</given-names></name><name><surname>Lohse</surname><given-names>M. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Measurement of the millisecond activation switch of G protein-coupled receptors in living cells</article-title>. <source/>Nat. Biotechnol.
<volume>21</volume>, <fpage>807</fpage>–<lpage>812</lpage>. <pub-id pub-id-type="doi">10.1038/nbt838</pub-id><pub-id pub-id-type="pmid">12808462</pub-id></mixed-citation>
</ref>
<ref id="B160">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilardaga</surname><given-names>J.-P.</given-names></name><name><surname>Romero</surname><given-names>G.</given-names></name><name><surname>Friedman</surname><given-names>P.</given-names></name><name><surname>Gardella</surname><given-names>T.</given-names></name></person-group> (<year>2011</year>). <article-title>Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm</article-title>. <source/>Cell. Mol. Life Sci.
<volume>68</volume>, <fpage>1</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-010-0465-9</pub-id><pub-id pub-id-type="pmid">20703892</pub-id></mixed-citation>
</ref>
<ref id="B161">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vohra</surname><given-names>S.</given-names></name><name><surname>Taddese</surname><given-names>B.</given-names></name><name><surname>Conner</surname><given-names>A. C.</given-names></name><name><surname>Poyner</surname><given-names>D. R.</given-names></name><name><surname>Hay</surname><given-names>D. L.</given-names></name><name><surname>Barwell</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Similarity between class A and class B G-protein-coupled receptors exemplified through calcitonin gene-related peptide receptor modelling and mutagenesis studies</article-title>. <source/>J. R. Soc. Interface
<volume>10</volume>:<fpage>20120846</fpage>. <pub-id pub-id-type="doi">10.1098/rsif.2012.0846</pub-id><pub-id pub-id-type="pmid">23235263</pub-id></mixed-citation>
</ref>
<ref id="B162">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Ardura</surname><given-names>J. A.</given-names></name><name><surname>Romero</surname><given-names>G.</given-names></name><name><surname>Yang</surname><given-names>Y. M.</given-names></name><name><surname>Hall</surname><given-names>R. A.</given-names></name><name><surname>Friedman</surname><given-names>P. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Na/H exchanger regulatory factors control parathyroid hormone receptor signaling by facilitating differential activation of g alpha protein subunits</article-title>. <source/>J. Biol. Chem.
<volume>285</volume>, <fpage>26976</fpage>–<lpage>26986</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.147785</pub-id><pub-id pub-id-type="pmid">20562104</pub-id></mixed-citation>
</ref>
<ref id="B163">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warne</surname><given-names>T.</given-names></name><name><surname>Moukhametzianov</surname><given-names>R.</given-names></name><name><surname>Baker</surname><given-names>J. G.</given-names></name><name><surname>Nehmé</surname><given-names>R.</given-names></name><name><surname>Edwards</surname><given-names>P. C.</given-names></name><name><surname>Leslie</surname><given-names>A. G. W.</given-names></name><etal></etal></person-group>. (<year>2011</year>). <article-title>The structural basis for agonist and partial agonist action on a beta(1)-adrenergic receptor</article-title>. <source/>Nature
<volume>469</volume>, <fpage>241</fpage>–<lpage>244</lpage>. <pub-id pub-id-type="doi">10.1038/nature09746</pub-id><pub-id pub-id-type="pmid">21228877</pub-id></mixed-citation>
</ref>
<ref id="B164">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>H.</given-names></name><name><surname>Au</surname><given-names>M.</given-names></name><name><surname>Bobby</surname><given-names>R.</given-names></name><name><surname>Archbold</surname><given-names>J.</given-names></name><name><surname>Abdul-Manan</surname><given-names>N.</given-names></name><name><surname>Moore</surname><given-names>J.</given-names></name><etal></etal></person-group>. (<year>2013</year>). <article-title>Identification of key residues involved in adrenomedullin binding to the AM1 receptor</article-title>. <source/>Br. J. Pharmacol.
<volume>169</volume>, <fpage>143</fpage>–<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1111/bph.12118</pub-id><pub-id pub-id-type="pmid">23351143</pub-id></mixed-citation>
</ref>
<ref id="B165">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wootten</surname><given-names>D.</given-names></name><name><surname>Simms</surname><given-names>J.</given-names></name><name><surname>Miller</surname><given-names>L. J.</given-names></name><name><surname>Christopoulos</surname><given-names>A.</given-names></name><name><surname>Sexton</surname><given-names>P. M.</given-names></name></person-group> (<year>2013</year>). <article-title>Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>110</volume>, <fpage>5211</fpage>–<lpage>5216</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1221585110</pub-id><pub-id pub-id-type="pmid">23479653</pub-id></mixed-citation>
</ref>
<ref id="B166">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>D. E.</given-names></name><name><surname>Rodbell</surname><given-names>M.</given-names></name></person-group> (<year>1979</year>). <article-title>Glucagon1-6 binds to the glucagon receptor and activates hepatic adenylate cyclase</article-title>. <source/>J. Biol. Chem.
<volume>254</volume>, <fpage>268</fpage>–<lpage>269</lpage>. <pub-id pub-id-type="pmid">216670</pub-id></mixed-citation>
</ref>
<ref id="B167">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Chien</surname><given-names>E. Y.</given-names></name><name><surname>Mol</surname><given-names>C. D.</given-names></name><name><surname>Fenalti</surname><given-names>G.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Katritch</surname><given-names>V.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists</article-title>. <source/>Science
<volume>330</volume>, <fpage>1066</fpage>–<lpage>1071</lpage>. <pub-id pub-id-type="doi">10.1126/science.1194396</pub-id><pub-id pub-id-type="pmid">20929726</pub-id></mixed-citation>
</ref>
<ref id="B168">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Q.</given-names></name><name><surname>Jeng</surname><given-names>W.</given-names></name><name><surname>Wheeler</surname><given-names>M. B.</given-names></name></person-group> (<year>2000</year>). <article-title>Characterization of glucagon-like peptide-1 receptor-binding determinants</article-title>. <source/>J. Mol. Endocrinol.
<volume>25</volume>, <fpage>321</fpage>–<lpage>335</lpage>. <pub-id pub-id-type="doi">10.1677/jme.0.0250321</pub-id><pub-id pub-id-type="pmid">11116211</pub-id></mixed-citation>
</ref>
<ref id="B169">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>T.</given-names></name><name><surname>Tose</surname><given-names>K.</given-names></name><name><surname>Shichida</surname><given-names>Y.</given-names></name></person-group> (<year>2008</year>). <article-title>First cytoplasmic loop of Glucagon-like Peptide-1 receptor can function at the third cytoplasmic loop position of rhodopsin†</article-title>. <source/>Photochem. Photobiol.
<volume>84</volume>, <fpage>931</fpage>–<lpage>936</lpage>. <pub-id pub-id-type="doi">10.1111/j.1751-1097.2008.00327.x</pub-id><pub-id pub-id-type="pmid">18363619</pub-id></mixed-citation>
</ref>
<ref id="B170">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X. J.</given-names></name><name><surname>Parnot</surname><given-names>C.</given-names></name><name><surname>Deupi</surname><given-names>X.</given-names></name><name><surname>Ratnala</surname><given-names>V. R. P.</given-names></name><name><surname>Swaminath</surname><given-names>G.</given-names></name><name><surname>Farrens</surname><given-names>D.</given-names></name><etal></etal></person-group>. (<year>2006</year>). <article-title>Coupling ligand structure to specific conformational switches in the beta(2)-adrenoceptor</article-title>. <source/>Nat. Chem. Biol.
<volume>2</volume>, <fpage>417</fpage>–<lpage>422</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio801</pub-id><pub-id pub-id-type="pmid">16799554</pub-id></mixed-citation>
</ref>
<ref id="B171">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X. J.</given-names></name><name><surname>Vélez Ruiz</surname><given-names>G. V.</given-names></name><name><surname>Whorton</surname><given-names>M. R.</given-names></name><name><surname>Rasmussen</surname><given-names>S. G.</given-names></name><name><surname>Devree</surname><given-names>B. T.</given-names></name><name><surname>Deupi</surname><given-names>X.</given-names></name><etal></etal></person-group>. (<year>2009</year>). <article-title>The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>106</volume>, <fpage>9501</fpage>–<lpage>9506</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0811437106</pub-id><pub-id pub-id-type="pmid">19470481</pub-id></mixed-citation>
</ref>
<ref id="B172">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yaqub</surname><given-names>T.</given-names></name><name><surname>Tikhonova</surname><given-names>I. G.</given-names></name><name><surname>Lattig</surname><given-names>J.</given-names></name><name><surname>Magnan</surname><given-names>R.</given-names></name><name><surname>Laval</surname><given-names>M.</given-names></name><name><surname>Escrieut</surname><given-names>C.</given-names></name><etal></etal></person-group>. (<year>2010</year>). <article-title>Identification of determinants of glucose-dependent insulinotropic polypeptide receptor that interact with N-terminal biologically active region of the natural ligand</article-title>. <source/>Mol. Pharmacol.
<volume>77</volume>, <fpage>547</fpage>–<lpage>558</lpage>. <pub-id pub-id-type="doi">10.1124/mol.109.060111</pub-id><pub-id pub-id-type="pmid">20061446</pub-id></mixed-citation>
</ref>
<ref id="B173">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>A. T.</given-names></name><name><surname>Bessalle</surname><given-names>R.</given-names></name><name><surname>Bisello</surname><given-names>A.</given-names></name><name><surname>Nakamoto</surname><given-names>C.</given-names></name><name><surname>Rosenblatt</surname><given-names>M.</given-names></name><name><surname>Suva</surname><given-names>L. J.</given-names></name><etal></etal></person-group>. (<year>1997</year>). <article-title>Direct mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking</article-title>. <source/>Proc. Natl. Acad. Sci. U.S.A.
<volume>94</volume>, <fpage>3644</fpage>–<lpage>3649</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.94.8.3644</pub-id><pub-id pub-id-type="pmid">9108031</pub-id></mixed-citation>
</ref>
<ref id="B174">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuckermann</surname><given-names>R. N.</given-names></name><name><surname>Kodadek</surname><given-names>T.</given-names></name></person-group> (<year>2009</year>). <article-title>Peptoids as potential therapeutics</article-title>. <source/>Curr. Opin. Mol. Ther.
<volume>11</volume>, <fpage>299</fpage>–<lpage>307</lpage>. <pub-id pub-id-type="pmid">19479663</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>